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Cigarette smoking represents the most preventable cause of morbidity and 
mortality in the world today, and is responsible for enormous health-related economic 
burdens. Among other medical sequelae, erectile impairment has been shown to be 
associated with chronic tobacco use. The primary aim of the present study was to provide 
the first empirical investigation of the effects of smoking cessation on physiological and 
subjective indices of sexual health. Sixty-five long-term, heavy smoking men participated 
in a smoking cessation program and were assessed at baseline (while smoking regularly), 
at mid-treatment (while using a high dose nicotine transdermal patch), and at 4-week 
follow-up. Physiological and subjective sexual arousal indices, as well as self-reported 
sexual functioning (as measured by the International Index of Erectile Functioning 
(IIEF)) were assessed during each visit. Intent-to-treat analyses indicated that at follow-
up successful quitters (n = 20), compared to those who relapsed (n = 45), showed 
significant improvements in physiological and subjective sexual arousal. Specifically, 
men demonstrated enhanced erectile responses, decreased latencies to reach maximum 
erectile capacity, and faster onset to reach maximum subjective sexual arousal. Although 
participants displayed across-session enhancements in self-reported sexual function, 
 vii 
successful quitters did not show a differential improvement compared to participants who 
relapsed. The results of the present investigation provide the first empirical evidence that 
smoking cessation significantly enhances both physiological and self-reported indices of 
sexual health in long-term male smokers, irrespective of baseline erectile impairment. It 
is hoped that these results may serve as a novel and enticing means to influence men to 
quit smoking. Increasing successful smoking cessation in men would significantly 
enhance quality of life, substantially reduce premature death, and alleviate enormous 
economic burdens caused by smoking-related diseases. 
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CHAPTER 1: INTRODUCTION 
1.1   Tobacco use: Prevalence and public health 
Tobacco use constitutes the single most preventable cause of disease and death in 
the world today (Centers for Disease Control and Prevention, 2002), and introduces a 
wide range of diseases such as cardiovascular diseases (e.g., coronary heart disease, 
peripheral vascular disease, hypertension, stroke (Fielding, Husten, & Eriksen, 1998)), 
respiratory diseases (Fagerström, 2002), and many types of cancer (U.S. Department of 
Health and Human Services, 2004). These smoking-related diseases reduce quality of life 
and shorten quantity of life by approximately 10 years (Doll, Peto, Boreham, & 
Sutherland, 2004). Each year, smoking is responsible for the deaths of over 269,000 men 
and 173,000 women in the United States (Centers for Disease Control and Prevention, 
2008b) and approximately 5 million premature deaths annually worldwide (Global Youth 
Tobacco Survey Collaborative Group, 2003). In fact, in the United States one in every 
five deaths is smoking related, which translates to an estimated $97 billion in health-
related economic losses each year (Centers for Disease Control and Prevention, 2008b).   
The prevalence of smoking, which is estimated at 1 billion worldwide, is slowly 
decreasing in industrialized countries and rising in developing countries, especially in 
Asia and Africa (Steptoe, et al., 2002). The worldwide death toll from smoking is 
expected to rise from 5 million to 10 million people per year by the year 2030 (Ezzati & 
Lopez, 2003). Data from the 2008 National Health Interview Survey (NHIS) reported that 
an estimated 20.6% of adults (46 million) in the United States are current cigarette 
smokers (Centers for Disease Control and Prevention, 2008a). Among these individuals, 
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smoking prevalence is slightly higher among men (23.1%) than women (18.3%). 
Although the prevalence is lower than reported in previous years, the rate of decline is 
not nearly sufficient to meet the National Health Service’s objective to reduce the 
prevalence of cigarette smoking among adults to <12% (Centers for Disease Control and 
Prevention, 2006).  
1.2 Erectile dysfunction 
1.2.1   Prevalence and public health 
Erectile dysfunction (ED) is defined in the DSM-IV-TR (American Psychiatric 
Association, 2000) as the recurrent inability to achieve or maintain adequate erection of 
the penis to engage in satisfactory sexual intercourse. Erectile dysfunction is estimated to 
affect 34 million men in the United States and more than 150 million men worldwide 
(Ayta, McKinlay, & Krane, 1999; Young, Bennett, Gilhooly, Wessells, & Ramos, 2002). 
By 2025 this prevalence is expected to double (Ayta, et al., 1999). Erectile dysfunction is 
considered a significant public health problem and has a strong negative effect on 
interpersonal relationships (Morokoff & Gillilland, 1993), well-being (Laumann, Paik, & 
Rosen, 1999), and quality of life (Fugl-Meyer, Lodnert, Branholm, & Fugl-Meyer, 1997; 
MacDonaugh, Ewings, & Porter, 2002).   
Prevalence, incidence, and severity of ED all increase with age. In a national 
probability sample of 1,410 men in the United States, Laumann, Paik, and Rosen (1999) 
reported that approximately 7% aged 18-29 years, 9% aged 30-39 years, 11% aged 40-49 
years, and 18% aged 50-59 years have erectile difficulties. A more recent cross-sectional 
analysis of 2,126 men in the Unites States (Selvin, Burnett, & Platz, 2007) revealed a 
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similar age-associated ED prevalence: approximately 5% aged 20-39 years, 15% aged 
40-59 years, 44% aged 60-69 years, and 70% over 70 years had erectile difficulties. Of 
the relatively limited studies that have evaluated the prevalence of ED in countries other 
than the United States, all have reported similar age-associated rates (Martin-Morales, et 
al., 2001; Ponholzer, et al., 2005; Shirai, et al., 1987; Solstad & Hertoft, 1993)  
1.2.2   Associated risk factors 
Erectile dysfunction can be classified as either organic or psychogenic (Benet & 
Melman, 1995). Organic ED may be caused by vascular or neurological diseases, 
hormonal irregularities, or by abnormalities or lesions of the penile smooth musculature 
(Melman & Gingell, 1999). Psychogenic ED is inhibition of the erectile mechanisms via 
central mediation and has no physical underpinnings (i.e., purely cognitive cause). It is 
recognized that in most patients with ED, both organic and psychogenic components 
exist (Melman & Gingell, 1999).  
It is now recognized that vascular diseases of the penile arteries are the most 
common causes of organic ED and account for up to 80% of cases (Donatucci & Lue, 
1993; D. R. Kaiser, et al., 2004; O'Kane & Jackson, 2001). Atherosclerotic disease is the 
cause of approximately 40% of men older than 50 years with ED (F. E. Kaiser, et al., 
1988). In patients with diabetes mellitus, the prevalence of ED ranges from 
approximately 40 - 50% (Chew, Earle, Stuckey, Jamroziki, & Keogh, 2000; McCulloch, 
Campbell, Wu, Prescott, & Clarke, 1980). This is irrespective of type of diabetes, but is 
dependent on patient age, duration of disease, and disease severity (Melman & Gingell, 
1999). Other medical conditions associated with a high prevalence of ED include 
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multiple sclerosis (Ghezzi, Malvestiti, Baldini, Zaffaroni, & Zibetti, 1995), Alzheimer’s 
disease (Zeiss, Davies, Wood, & Tinklenberg, 1990), renal failure (Kaufman, 
Hatzichristou, Mulhall, Fitch, & Goldstein, 1994), hepatic failure (Bortolotti, Parazzini, 
Colli, & Landoni, 1997), hyperlipidemia (Ponholzer, et al., 2005), and chronic 
obstructive lung disease (Fletcher & Martin, 1982; Köseoğlu, et al., 2005). Endocrine 
disorders, such as hypothyroidism and hypogonadism, may also induce ED (Soran & Wu, 
2005), as may prostate disease and prostate surgery (Melman & Gingell, 1999).  
Many medications and recreational drugs are associated with organic ED. 
However, it is often difficult to delineate whether the pharmacological agent, or the 
condition for which the drug is being taken, is primarily responsible. Benzodiazepines 
and certain diuretics unequivocally contribute to ED (Derby, Babour, Hume, & 
McKinlay, 2001). Selective serotonin reuptake inhibitors (SSRIs) (Lane, 1997; R. C. 
Rosen, Lane, & Menza, 1999) have also been demonstrated to induce ED.  
Among lifestyle factors, smoking (Tengs & Osgood, 2001), obesity (Derby, et al., 
2000), and physical inactivity (Derby, et al., 2000) have been associated with elevated 
risk for ED. Mixed results have been reported on the relation between alcohol 
consumption and male sexual dysfunction (Cornely, Schade, Van Thiel, & Gavaler, 
1984; Jensen, 1984; Schiavi, Stimmel, Mandelli, & White, 1995; Whalley, 1978).  
Psychogenic erectile dysfunction is much more prevalent in younger men and 
accounts for up to 70% of patients younger than 35 years and only 10% of men older than 
50 years (Slag, et al., 1983). Some risk factors affecting psychogenic ED include 
performance anxiety, stress, depression, relationship difficulties, and anger suppression 
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(Araujo, Durante, Feldman, Goldstein, & McKinlay, 1998; Feldman, Goldstein, 
Hatzichristou, Krane, & McKinlay, 1994; Lue, 2000; Melman & Gingell, 1999; R. C. 
Rosen, 2001).   
1.3 The link between cigarette smoking and erectile dysfunction 
1.3.1   Extant smoking 
Epidemiological studies demonstrate a clear link between cigarette smoking and 
sexual dysfunction in men. Large cross-sectional studies (Dorey, 2001; He, et al., 2007; 
Jeremy & Mikhailidis, 1998; Lam, Abdullah, Ho, Yip, & Fan, 2006; Mannino, Klevens, 
& Flanders, 1994; Ponholzer, et al., 2005) indicate that chronic smokers are 
approximately 1.5 to 2 times as likely as nonsmokers to report ED, even after controlling 
for age and confounding cardiovascular risk factors. In fact, a meta-analysis of 19 studies 
(N = 3819) over two decades revealed that 40% of men with ED were current smokers 
compared with 28% of men in the general population (Tengs & Osgood, 2001). 
Interestingly, it has been reported that the magnitude of association between smoking and 
ED decreases across increasingly older age groups. This suggests that smoking may have 
a stronger deleterious effect on sexual functioning in young male smokers compared to 
older male smokers (Gades, et al., 2005).  
To my knowledge, only one study has longitudinally investigated the association 
between smoking and ED (Feldman, et al., 2000). Over 500 men reporting no lifetime 
incidence of diabetes, heart disease or cardiovascular conditions, and with no erectile 
dysfunction, were assessed at baseline. A follow up 8 years later indicated that smokers 
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were approximately 2 times as likely than nonsmokers to have moderate or complete 
erectile dysfunction (24% versus 14%; adjusted odds ratio = 1.97). 
1.3.2 Prior smoking 
Several cross-sectional studies have demonstrated an association with prior 
smoking and current ED (Bortolotti, et al., 1997; Mannino, et al., 1994; Mirone, et al., 
2002). In an extensive review of the literature concerning ED and chronic tobacco use 
(McVary, Carrier, Wessells, & Subcommittee on Smoking and Erectile Dysfunction 
Socioeconomic Committee Sexual Medicine Society of North America, 2001), it has 
been shown that the nearly two-fold risk of ED decreases substantially in the initial 2-3 
years after successfully quitting. Thereafter, the risk reduction decelerates, taking a full 
10 years post-cigarette cessation for former smokers to achieve the risk level of never-
smokers. However, a prospective study found no change in ED status among individuals 
who quit smoking for 8 years (Derby, et al., 2000), suggesting permanent smoking-
induced vascular damage.  
1.3.3   Passive smoking 
Evidence also suggests an association between passive smoking and erectile 
function, with men exposed to passive smoke exposure having twice the risk of 
developing ED (Feldman, et al., 2000). Passive smoking may also reduce coronary flow 
velocity in healthy nonsmokers, potentially leading to endothelial dysfunction (Otsuka, et 
al., 2001). Regular passive exposure to tobacco smoke at home or work also increases the 
risk of coronary heart disease among nonsmokers (Kawachi, et al., 1997). Therefore, it is 
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reasonable to believe that passive smoking may induce erectile difficulties by 
precipitating vascular diseases.   
1.3.4   Dose response 
 The dose-dependent relationship between cigarette smoking and ED has been 
explored in several studies and results appear to demonstrate an association between the 
intensity of cigarette smoking and severity of erectile difficulties. Specifically, heavy 
smokers appear to exhibit a higher risk of ED compared to moderate or light smokers 
(Gades, et al., 2005; Mirone, et al., 2002; Natali, Mondaini, Lombardi, Del Popolo, & 
Rizzo, 2005). In one particular study, Natali and colleagues (2005) demonstrated that the 
prevalence of ED is 2.5 times higher in heavy smokers compared to light smokers (43% 
vs. 17%, respectively). Conversely, other studies have found no differential risk of ED 
associated with the number of years smoked or the number of cigarettes smoked daily 
(Feldman, et al., 1994; Mannino, et al., 1994).   
1.4   Penile erection physiology 
1.4.1   Hemodynamics 
Genital vasocongestion in the human male is a complex neurovascular event and 
has been reviewed extensively (Andersson & Wagner, 1997). Penile erection and 
detumescence are characterized by complementary hemodynamic processes (Taub, 
Lerner, Melman, & Christ, 1993). In the flaccid state, the cavernous smooth musculature 
and the smooth muscles of the arteriolar walls are tonically contracted, thereby enabling 
only a small amount of arterial inflow necessary for oxygenation (Dean & Lue, 2005). 
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After sexual stimulation (cognitive or somatic), the parasympathetic nervous system 
triggers the release of neurotransmitters from cavernous nerve terminals. This results in a 
decrease in peripheral resistance due to vasodilation and increased arterial inflow. 
Simultaneously, compression of the subtunical venular plexuses reduces venous outflow, 
resulting in penile engorgement and erection (Dean & Lue, 2005). Penile detumescence is 
largely under sympathetic nervous system control, which returns arterial blood flow to its 
prestimulation level, opens venous outflow channels, decreases intracavernosal pressure, 
and deactivates the veno-occlusive mechanism, returning the penis to its flaccid state 
(Melman & Gingell, 1999).  
1.4.2   Neurotransmission and neuropeptide factors 
 In response to sexual stimulation, the parasympathetic nervous system triggers the 
release of acetylcholine which binds to cholinergic receptors on the corpus cavernosum 
(Meston & Frohlich, 2000), causing smooth muscle relaxation. Additionally, the 
cavernous nerves and endothelial cells release nitric oxide (NO) which has been 
identified as the principal neurotransmitter mediating penile erection (Burnett, 
Lowenstein, Bredt, Chang, & Snyder, 1992; Kim, Azadzoi, Goldstein, & Saenz de 
Tejada, 1991). Endothelial cells within the penis produce NO with enzyme nitric oxide 
synthase (eNOS). Enzyme nitric oxide synthase isoforms convert L-arginine to NO and 
other biochemical constituents (McVary, et al., 2001). Nitric oxide promotes the 
production of cyclic guanosine monophosphate (cGMP) in the vascular system (R. C. 
Rosen & McKenna, 2002). The interplay between NO and cGMP is responsible for 
relaxing cavernous smooth muscle cells and increases arterial inflow to the sinusoids, 
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promoting penile tumescence while also decreasing venous outflow. Detumescence, on 
the other hand, is modulated by the sympathetic nervous system via the release of 
norepinephrine and activation of postsynaptic α1-adrenergic receptors (Lincoln & 
Cornell, 1991).   
 Several neuropeptides interact with the NO dependent pathways of erectile 
function. Corporal endothelial cells synthesize and release endothelin, which acts as a 
vasoconstrictor and precipitates the contractile responses of the penile musculature 
(Saenz de Tejada, Carson, de las Morensas, Goldstein, & Traish, 1991). Vasoactive 
intestinal polypeptide has also been implicated in the biochemical pathways of erectile 
function (Melman & Gingell, 1999).    
1.4.3   Endocrine factors 
Testosterone plays a major role in men’s sexual function and influences the growth 
and development of the male reproductive tract and secondary sex characteristics. The 
effects of androgens on libido and sexual behavior are well established. Testosterone 
regulates sexual desire, frequency of sexual activity, frequency of nocturnal erections, 
and erectile responses (Traish, Kim, Traish, & Kim, 2005). Decreased testosterone has 
been associated with erectile impairments (Guay, 2006). Studies in castrated animals 
have reported a decreased arterial inflow, venous leakage, and dramatically reduced 
erectile response (Mills, Stopper, & Wiedmeier, 1994; Penson, Ng, Cai, Rajfer, & 
Gonzalez-Cadavid, 1996). Importantly, studies have also demonstrated that the addition 
of testosterone, and its conversion to dihydrotestosterone, can restore erectile function 
(Baba, Yajima, Carrier, Akkus, et al., 2000; Baba, Yajima, Carrier, Morgan, et al., 2000). 
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It appears that testosterone achieves this by peripheral mechanisms (endothelial 
dependent and independent) and central mechanisms. Testosterone replacement therapy 
is therefore effective for erectile dysfunction in men with hypogonadism, with success 
rates of 35-40% (Guay, 2006).  
1.4.4   Central nervous system 
Studies in both animals and humans have helped to elucidate several brain areas 
that play a role in erection physiology. Studies in animals have delineated the important 
function of the medial preoptic area (MPOA) and the paraventricular nucleus (PVN) of 
the hypothalamus and hippocampus. In fact, electrostimulation of this area induces penile 
tumescence, and lesions at this site limit copulation (Marson, Platt, & McKenna, 1993). 
Several brainstem and medullary regions, as well as the forebrain are also involved in 
sexual function (Meston & Frohlich, 2000).  
1.5   Effects of tobacco smoke/nicotine on mechanisms underlying male sexual 
arousal 
Pathophysiological underpinnings of tobacco-induced ED have been proposed in 
response to the wide range of research examining the effects of cigarette smoking on 
biochemical mechanisms underlying vascular functioning (Mazo, Gamidov, Anranovich, 
& Iremashvili, 2005). Nicotine (which is the most important compound responsible for 
acute cardiovascular effects of smoking) increases heart rate, myocardial contractability, 
and blood pressure - effects which are primarily due to stimulation of sympathetic 
neurotransmission. Cigarette smoking decreases penile arterial inflow (McMahon & 
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Touma, 1999) and disrupts veno-occlusive mechanisms (Elhanbly, et al., 2004), resulting 
in deficiency of genital vasoengorgement. These disruptions are mediated by a 
deregulation in endothelium smooth muscle relaxation (Mazo, et al., 2005). Additionally, 
experimental evidence indicates that chronic nicotine exposure has deleterious effects on 
modulating the release of adrenaline and noradrenaline (Jeremy & Mikhailidis, 1998) 
which may compromise erectile functioning. 
 
Figure 1. Presumed Mechanisms of Action Responsible for Smoking-Induced Altered Smooth Muscle 
Relaxation.  
Free radicals and aromatic compounds diminish endothelial synthesis of nitric oxide (NO) by affecting enzyme nitric 
oxide synthase (eNOS), causing impaired endothelium dependent relaxation of arteries. This may result from reduction 
in activity of endothelial nitric oxide synthase that is attributable to inadequate supply of coenzyme tetrahydrobiopterin. 
Smoke also causes contraction of smooth muscle by superoxide anion mediated degradation of nitric oxide. Ach-R, 
acetylcholine receptor. VEGF, vascular endothelial growth factor. VEGF-R, vascular endothelial growth factor 




Biochemical processes underlying erection physiology may also be affected by 
chronic smoking. Nitric oxide produced within penile endothelial cells has been 
identified as the principal neurotransmitter mediating erection (Burnett, et al., 1992; Kim, 
et al., 1991). Free radicals and other compounds within cigarettes may decrease the 
endothelial synthesis of NO directly, or indirectly by targeting precursors (disrupting the 
activity of enzyme nitric oxide synthase (eNOS) thereby disrupting the conversion of L-
arginine to NO), resulting in decreased penile blood inflow (see Figure 1) (McVary, et 
al., 2001; Zhang, Venardos, Chin-Dusting, & Kaye, 2006). This may have significant 
long-term effects on erectile functioning. Tobacco inhalation also exerts neuroendocrine 
effects, affecting pituitary, thyroid, adrenal, and testicular function (Kapoor & Jones, 
2005), which may affect erectile responses.  
In sum, nicotine and/or particular tobacco compounds may deleteriously affect the 
mechanisms underlying sexual arousal in the following ways: (i) centrally, by eliciting 
dose-dependent neurotransmitter and neuroendocrine effects (Pomerleau, 1992); (ii) 
peripherally, by acting as a sympathetic nervous system (SNS) agonist (Haass & Kübler, 
1997); or (iii) by disrupting NO synthesis directly or indirectly by targeting biochemical 
precursors. Complex interactions among these pathways may also exist (Sartori, Lepori, 
& Scherrer, 2005). 
1.6   Acute effects of tobacco smoke on male sexual arousal 
Few studies have focused on the acute effects of smoking on physiological sexual 
response. One animal study (Juenemann, et al., 1987) assessed the effects of 7 to 12 
minutes of acute smoke exposure on penile erection in dogs. After smoke ingestion 
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equivalent to 2 to 3 cigarettes, 5 of 6 dogs did not achieve complete erection during 
neurostimulation. Both arterial inflow via the internal pudental artery and veno-occlusion 
ability were impaired, with almost complete ineffectiveness of venous restriction. 
Additionally, the same phenomena were observed after intravenous administration of 
pure nicotine. Another study investigated the effect of 8 weeks of passive smoking on 
erectile functioning in rats. Although eNOS expression was reduced, no impairment of 
erection was demonstrated during neurostimulation (Xie, Garban, Ng, Rajfer, & 
Gonzalez-Cadavid, 1997).  
To my knowledge, there has only been one experimental study involving the 
acute effects of cigarette smoking on human sexual arousal. Gilbert, Hagen and 
D’Agostino (1986) tested 42 male smokers who were randomly assigned to nicotine, 
placebo, or wait list conditions. Participants who smoked three 0.9-mg nicotine cigarettes 
within one half-hour – relative to men who smoked three placebo cigarettes, and to men 
who had not smoked – experienced significantly attenuated physiological sexual arousal.  
1.7   Acute effects of nicotine on male sexual arousal 
Experimental studies examining acute effects of tobacco inhalation on 
physiological sexual arousal help to elucidate underlying physiological mechanisms that 
may be responsible for introducing and/or maintaining erectile impairment. However, 
because chronic cigarette smoking may cause vascular duration-dependent degeneration 
(Pittilo & Woolf, 1993), uncertainty arises as to whether the acute effects of tobacco 
smoke on sexual arousal differentially affect long-term smokers compared to 
nonsmokers. Additionally, because cigarettes contain over 4000 active pharmacological 
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constituents (Chien, 1994), the primary element or group of interacting compounds 
responsible for the deleterious effects of smoking on sexual response remains unclear.  
In an attempt to address these issues, Harte and Meston (2008a) conducted the 
first empirical investigation examining the acute effects of isolated nicotine on sexual 
arousal in nonsmoking men measured both physiologically and subjectively. Twenty-
eight sexually functional heterosexual men, each with less than 100 direct exposures to 
nicotine, participated in a double-blind, randomized, placebo-controlled, crossover trial. 
Participants received either 6mg of nicotine gum (approximately equivalent to smoking 
one high-yield cigarette) or placebo gum approximately 40 minutes prior to viewing an 
erotic film. Results indicated that nicotine, compared to placebo, significantly reduced 
erectile responses to the erotic films, corresponding to a 23% reduction in physiological 
sexual arousal. Nicotine had no significant effect on subjective ratings of sexual arousal, 
or on mood.  
These findings suggest that the reduction in physiological sexual response 
resulting from nicotine intake was not likely mediated by nicotine-induced changes in 
cognitive states. This further supports the hypothesis that nicotine may directly or 
indirectly precipitate genital hemodynamic disruption via peripheral or central activation 
of the nervous system. This finding was in accordance with those of other studies 
examining the deleterious acute effects of isolated nicotine on sexual arousal (Klinge, 
Alaranta, & Sjöstrand, 1988) and peripheral vasculature (Chalon, Moreno, Benowitz, 
Hoffman, & Blaschke, 2000). Although this study indicated that nicotine impairs sexual 
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arousal acutely in healthy, sexually functional, nonsmokers, it is unknown whether these 
results generalize to individuals who are long-term smokers. 
1.8 Effects of smoking cessation on erectile function 
1.8.1   Prior studies 
Considering the robust evidence demonstrating the link between cigarette 
smoking and ED, an intervention that has the broadest health impact is smoking 
cessation. To my knowledge only two studies have investigated the effects of smoking 
cessation on erectile function. Sighinolfi and associates (2007) tested 20 heavy smokers 
(20 to 40 cigarettes/day), who had all been smoking for at least five years, and who met 
criteria for ED according to an established questionnaire. Penile hemodynamic responses 
were measured with Doppler ultrasonography during baseline (while smoking) and acute 
follow-up (while smoke-free). Results indicated a significant improvement in penile 
blood flow within 24 to 36 hours of smoking discontinuation, suggesting that quitting 
smoking can potentially facilitate the remission of ED. 
Similarly, Guay and colleagues (1998) measured nocturnal penile tumescence and 
rigidity in 10 male smokers via a portable home monitor. Results showed significant 
improvement 24 hours after smoking cessation for both penile rigidity and tumescence. 
Of the 10 patients, 100% displayed improvements in both base and tip tumescence; 90% 
and 100% exhibited improvements in base and tip rigidity, respectively. They also 
assessed four men 1 month later, a period during which they wore a daily 21-mg nicotine 
transdermal patch. Examination of mean responses indicated a trend for continued 
improvement. Examining the four cases individually, it was shown that 2 of 4 men 
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displayed the highest tumescence during the nicotine patch regimen, the lowest 
tumescence during smoking, and a moderate level of tumescence during smoking 
cessation. The other two men displayed similar levels of tumescence during the patch 
treatment and while smoking, with enhanced tumescence during smoking cessation. With 
respect to rigidity, 3 of 4 men demonstrated a pattern characterized by lowest rigidity 
during smoking, moderate rigidity during nicotine treatment, and highest rigidity while 
not smoking. Guay and colleagues (1998) concluded that smoking-induced ED may not 
necessarily be due to the presence of nicotine, but rather caused by other psycho-
pharmacologically active ingredients found within cigarettes (e.g., carbon monoxide, tar, 
noxious gases). It should be noted that involuntary erection (nocturnal penile tumescence) 
was measured, and therefore how isolated nicotine and cigarette smoking affects 
voluntary sexual arousal (in response to erotic stimulation) remains unknown.   
1.8.2   Limitations 
These studies provide an excellent foundation for examining the relationship 
between smoking and sexual health; however, they are not without their limitations. First, 
these studies have only assessed individuals with clinically diagnosed erectile 
dysfunction, and therefore it remains unclear how smoking cessation affects sexual 
arousal responses in nonclinical individuals. Considering that the majority of smokers 
(under 60 years of age) would be expected to not have ED, it is important to investigate 
the association between smoking cessation and sexual health among all men, both with 
and without erectile difficulties. 
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Second, these studies have only included one outcome measure (physiological 
sexual arousal). Although improvement in erectile capacity was demonstrated in these 
studies, it is unclear how these physiological changes correspond to changes of a clinical 
nature. That is, does a statistically significant improvement in penile response translate to 
a clinically significant change, such that a patient either does not meet criteria for ED, or 
at least significantly improves his sexual health as assessed by validated construct-
specific measures? Incorporating gold-standard self-report measures of sexual arousal 
and sexual functioning would help address these questions and would be an ecologically 
valid way of assessing changes in sexual health. 
Third, these studies have only tested acute effects (24 – 36 hours) of quitting 
smoking and have not tested men at a later follow-up. Moreover, because of the acute 
nature of these follow-up assessments, these studies tested men who quit smoking 
spontaneously (“cold-turkey”). Therefore, it is reasonable to believe that both 
physiological and psychological nicotine withdrawal effects could have affected results. 
With this in mind, it may be important for studies to assess sexual functioning in men at a 
later follow-up period, after they have successfully quit smoking and are no longer 
experiencing undesirable side effects.     
Fourth, these studies have only included a treatment group comprised of 
individuals undergoing the cessation process; that is, these studies have not compared an 
experimental group to a control condition. As such, it remains uncertain as to whether 
changes in erectile response are primarily attributable to smoking cessation, or rather to 
potential confounding variables (e.g., threats to internal validity such as testing effects).      
 18
Fifth, because long-term cigarette smoking can cause vascular degeneration 
(Pittilo & Woolf, 1993; Powell, 1998), it is reasonable to believe that smoking cessation 
may differentially enhance smokers’ sexual arousal responses as a function of their 
lifetime cigarette consumption. Future studies would benefit from statistically controlling 
for the number of pack years for which a participant has smoked. It is the goal of this 
study to redress these limitations. 
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CHAPTER 2: THE PRESENT STUDY 
2.1   Brief overview 
The present study attempted to examine the effects of smoking cessation on 
sexual health in long-term smoking men. Physiological and self-reported indices of 
sexual health, as well as autonomic activity were assessed at three time intervals: (i) at 
baseline, while participants were regularly smoking; (ii) at mid-treatment, while using a 
21-mg nicotine transdermal patch; and (iii) at follow-up, four weeks after nicotine patch 
cessation. To my knowledge, this is the first study examining sexual function and 
smoking cessation that: (i) recruited individuals with and without erectile dysfunction; 
(ii) used several indices of sexual health measured psychophysiologically (erectile 
tumescence, continuous subjective arousal), and by self-report (erectile function, sexual 
satisfaction, sexual desire); (iii) assessed for clinical significance with respect to self-
report measures of sexual function; (iv) assessed intermediate (i.e., 4 weeks post-
cessation) effects of smoking cessation with respect to indices of sexual health; and (v) 
compared outcome measures between successful quitters and those who relapsed. 
2.2 Specific aims and hypotheses 
 Aim 1: To investigate within- and between-group changes in physiological sexual 
arousal. Among successful quitters, it was hypothesized that these participants would 
display significantly higher physiological arousal responses during post-cessation follow-
up, compared to both the mid-treatment assessment (while using a 21-mg nicotine patch) 
and the pre-treatment assessment (while smoking regularly). Furthermore, it was believed 
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that these participants would show increased physiological sexual arousal at mid-
treatment compared to pre-treatment (as a function of eliminating habitual intake of 
noxious gases found in cigarette smoke). I was uncertain as to whether this difference 
would be statistically significant, as nicotine alone may play an important role in 
inhibiting sexual arousal (Harte & Meston, 2008a, 2008c).  
 With respect to the entire sample of participants (both successful and unsuccessful 
quitters), I expected that there would be no between-group differences at baseline and 
mid-treatment. However, it was expected that at follow-up, successful quitters would 
display significant increases in physiological sexual arousal responses compared to 
relapsers.  
Aim 2: To investigate within- and between-group changes in continuous 
subjective sexual arousal. To my knowledge, no studies have investigated the effects of 
smoking cessation on self-reported sexual arousal. In nonsmoking men without ED, it has 
been shown that continuous measurements of subjective sexual arousal remained 
unaffected despite reduction in genital arousal (Harte & Meston, 2008a). This may 
suggest that nicotine attenuates genital arousal directly via physiological mechanisms, 
rather than impacting cognitive processes. However, it is unknown how smoking may 
affect self-reported arousal in habitual smokers or men with erectile difficulties. It is 
possible that over time, smokers may synchronize their self-reported sexual arousal to 
match their inhibited physiological sexual arousal. In other words, because men have a 
relatively salient physiological feedback system (i.e., penile erection), visuosensory 
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awareness of genital arousal provides significant feedback for subjective appraisals of 
sexual arousal (Sakheim, Barlow, Beck, & Abrahamson, 1984).  
It was hypothesized that all participants would demonstrate the same within- and 
between-group patterns of both subjective sexual arousal and physiological sexual 
arousal. Thus, among successful quitters, subjective sexual arousal was expected to 
increase as a result of smoking cessation, resulting in no between-group differences at 
baseline and mid-treatment, but significant group differences at follow-up.  
Aim 3: To investigate within- and between-group changes in self-reported sexual 
function. It was also hypothesized that erectile functioning measured via a self-report 
questionnaire (the International Index of Erectile Function (IIEF); (R. C. Rosen, et al., 
1997)) (see Appendix A) would show a similar pattern of within- and between-group 
results as compared to sexual arousal measured physiologically. Specifically, it was 
hypothesized that successful quitters would display significantly higher mean self-
reported erectile functioning scores at follow-up compared to both the pre-treatment and 
mid-treatment assessments. Additionally, I expected that the proportion of successful 
quitters meeting criteria for erectile dysfunction (as per the IIEF) would significantly 
decrease from baseline to both mid-treatment and follow-up.  
Among successful quitters, orgasmic function, intercourse satisfaction, and 
overall sexual function domains of the IIEF were also expected to increase in a 
statistically significant pattern similar to the erectile functioning domain. Finally, sexual 
desire and overall satisfaction domains were expected to show similar across session 
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patterns; however I was uncertain as to whether any of these changes would be 
statistically significant.  
With respect to unsuccessful quitters, it was expected that these individuals would 
show no across-session changes on any of the IIEF domains, resulting in group×time 
interaction effects for each sexual function variable. An overview of all general aims and 
specific hypotheses regarding specific outcome variables associated with each general 
aim are shown in Tables 1 and 2.  
2.3 Potential implications  
If successful quitters (compared to unsuccessful quitters) do in fact demonstrate a 
significant increase in sexual function as a result of smoking cessation, the results of this 
project may serve as a novel means to facilitate programs and interventions targeting the 
prevention and cessation of cigarette smoking in men. In particular, it is my hope that the 
results herein may influence healthcare providers to discuss the benefits of quitting 
smoking with male patients. Enhancing successful smoking cessation in men would 
significantly enhance quality of life, substantially reduce premature death, and alleviate 














Aim 1 – Indices of physiological sexual  
               arousal       
      Magnitude of change in penile  
           tumescence (cm) ? ↑ ↑ 
      Percent change in penile tumescence ? ↑ ↑ 
      Maximum arousal (cm) ? ↑ ↑ 
      Percent change in maximum arousal ? ↑ ↑ 
      Latency to reach maximum arousal (sec) ? ↓ ↓ 
      Rate of onset to maximum erection (slope) ? ↑ ↑ 
Aim 2 – Indices of self-reported sexual  
               arousal       
      Percent change in arousal ? ↑ ↑ 
      Latency to reach maximum arousal (sec) ? ↓ ↓ 
      Rate of onset to maximum arousal (slope) ? ↑ ↑ 
Aim 3 – Indices of self-reported sexual  
               functioning*       
      Mean erectile function score ? ↑ ↑ 
      Mean orgasmic function score ? ↑ ↑ 
      Mean sexual desire score ? ? ? 
      Mean intercourse satisfaction score ? ↑ ↑ 
      Mean overall satisfaction score ? ? ? 
      Mean overall sexual functioning  
           (total score) ? ↑ ↑ 
      Percentage meeting criteria for ED† ? ↓ ↓ 
 
 
Table 1. Overview of Aims and Hypotheses for the Subgroup of Successful Quitters.  
Upward arrows indicate statistically significant increases. Downward arrows indicate statistically significant 
decreases. Question marks denote uncertainty regarding statistical significance. All hypotheses pertain to the 
group of successful quitters Unsuccessful quitters were not expected to show any across-session changes. 
Abbreviations: ED = erectile dysfunction 
*As per the International Index of Erectile Function (IIEF). 




Baseline Mid-treatment Follow-up 
Aim 1 – Indices of physiological sexual  
               arousal       
      Magnitude of change in penile  
           tumescence (cm) SQ = UQ SQ = UQ SQ > UQ 
      Percent change in penile tumescence SQ = UQ SQ = UQ SQ > UQ 
      Maximum arousal (cm) SQ = UQ SQ = UQ SQ > UQ 
      Percent change in maximum arousal SQ = UQ SQ = UQ SQ > UQ 
      Latency to reach maximum arousal (sec) SQ = UQ SQ = UQ SQ < UQ 
      Rate of onset to maximum erection (slope) SQ = UQ SQ = UQ SQ > UQ 
Aim 2 – Indices of self-reported sexual  
               arousal    
      Percent change in arousal SQ = UQ SQ = UQ SQ > UQ 
      Latency to reach maximum arousal (sec) SQ = UQ SQ = UQ SQ < UQ 
      Rate of onset to maximum arousal (slope) SQ = UQ SQ = UQ SQ > UQ 
Aim 3 – Indices of self-reported sexual  
               functioning*    
      Mean erectile function score SQ = UQ SQ = UQ SQ > UQ 
      Mean orgasmic function score SQ = UQ SQ = UQ SQ > UQ 
      Mean sexual desire score SQ = UQ ? ? 
      Mean intercourse satisfaction score SQ = UQ SQ = UQ SQ > UQ 
      Mean overall satisfaction score SQ = UQ ? ? 
      Mean overall sexual functioning  
           (total score) SQ = UQ SQ = UQ SQ > UQ 
      Percentage meeting criteria for ED† SQ = UQ SQ = UQ SQ < UQ 
Table 2. Overview of Aims and Hypotheses for Between-Group Analyses of all Participants.  
Question marks denote uncertainty regarding statistical significance. 
Abbreviations: ED = erectile dysfunction; SQ = successful quitters; UQ = unsuccessful quitters. 
*As per the International Index of Erectile Function (IIEF). 
†According to an IIEF-erectile function cutoff score of 25.  
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CHAPTER 3: RESEARCH DESIGN, MATERIALS, AND METHODS 
3.1 Overview of experimental design 
This was a 12-week treatment study examining the effects of a smoking cessation 
intervention on sexual arousal responses in men. After participating in an initial 
telephone screening, participants who expressed a committed desire to quit smoking were 
invited to the Sexual Psychophysiology Laboratory at the University of Texas at Austin, 
and multimodal assessments of sexual functioning were conducted. Participants were re-
assessed at mid-treatment, while using a nicotine patch, and at 1-month follow-up.  
3.2   Participants  
3.2.1   Overview of participants  
Long-term male smokers (N = 65) aged 23-60, irrespective of erectile functioning, 
and who were motivated to quit smoking, were recruited through online advertisements, 
and via flyers throughout the Austin, Texas area. During the telephone screening, 
smoking participants were questioned on their pre-smoking sexual functioning and only 
those individuals who reported no sexual dysfunction prior to smoking onset were 
eligible to enroll in the study. Subject inclusion and exclusion criteria are listed below 
along with a brief description of the rationale underlying several key decisions 
concerning subject selection. All medical exclusionary criteria were based on self-report 
rather than via medical records.  
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3.2.2   Inclusion/exclusion criteria 
Inclusion criteria for participants were as follows: 
1) Men aged 23-60 years. The lower age limit of 23 years was implemented in 
order to allow sufficient time for participants to smoke legally for at least 5 
years (see criterion 5). The upper age criterion is implemented in order to 
minimize the age-associated increase in the prevalence of erectile impairment, 
irrespective of smoking (see Laumann et al. (1999), and Selvin et al. (2007) 
for review).  
2) Proficient in English. Participants were required to be fluent in English in 
order to enroll in the study because most of the self-report instruments have 
not been translated or validated in languages other than English, and there are 
no appropriate alternative instruments that meet this criterion.  
3) Heterosexual. Only heterosexual participants were recruited because the gold-
standard sexual function measure has not been validated within gay or 
bisexual populations. Heterosexuality will be operationally defined as self-
report of exclusive, or predominant opposite gender sexual feelings and/or 
behaviors (i.e., scores of 0, 1, or 2) as assessed using the Kinsey Sexual 
Orientation Scale (see Appendix B) (Kinsey, Pomeroy, & Martin, 1948). 
4)  Involved in a heterosexual relationship in which a participant is willing to 
engage in at least one sexual encounter per week. This was to ensure 
sufficient opportunity to assess the clinical benefits of smoking cessation in 
the patients' natural setting. Furthermore, the erectile function measure 
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(International Index of Erectile Function (IIEF) (R. C. Rosen, et al., 1997)) 
required that participants be sexually active with a partner. 
5) Smoking at least 15 cigarettes per day cigarettes for a minimum of 5 
consecutive years. This was to ensure that participants had sufficient exposure 
to tobacco smoke.  
6) No sexual dysfunction prior to smoking onset. 
7) Motivated and committed to quit smoking. 
 
Exclusion criteria for participants were as follows: 
1) Under the age of 23 or over the age of 60. see inclusion criteria above. 
2) History of HIV infection or active, untreated pelvic or urinary tract infection 
including, sexually transmitted diseases such as chlamydia genital herpes, 
gonorrhea, or syphilis. 
3) Major pelvic surgery that may have caused nerve damage, or serious 
bladder, rectal, or abdominal surgery. This was to rule out underlying neural 
conditions as a cause for erectile difficulties. 
4) Neurological impairment due to diabetes, stroke, pelvic nerve damage 
secondary to trauma, cancer treatments, myasthenia gravis, multiple 
sclerosis or spinal cord damage. 
5) Clinically significant untreated renal or endocrine disease. 
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6) Uncontrolled hypotension or hypertension manifested by systolic blood 
pressure >170 or <90 mm Hg or diastolic blood pressure >100 or <50 mm 
Hg. 
7) History of serious drug abuse or serious alcohol abuse during the past 12 
months. To rule out serious drug and alcohol abuse and/or dependence, 
participants must score < 16 points on the Alcohol Use Disorders 
Identification Test (AUDIT; see Appendix C) (J. Saunders, Aasland, Babor, 
de la Fuente, & Grant, 1993)  and < 6 on the Drug Abuse Screening Test 
(DAST-10; see Appendix D) (Skinner, 1982).  
8) Evidence of schizophrenia, delusional disorder, or psychotic disorders not 
classified elsewhere. This was to minimize the possibility that symptoms 
associated with these disorders could mask the therapeutic benefits of 
smoking cessation on sexual function. 
9) Not involved in a heterosexual relationship in which an individual was 
willing to engage in at least one sexual encounter per week. See inclusion 
criteria above.   
10) Participants who posed a current, serious suicidal or homicidal risk. 
11) Participants using medications known to affect sexual or vascular 
functioning. These medications included antidepressants, anti-hypertensives, 
and hormone supplements, as well as sildenafil, vardenafil, tadalafil, or any 
other substance designed to affect sexual performance.  
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12) Participants using insulin, narcotic pain relievers (propoxyphene, 
pentazocine), oxazepam, or medications for respiratory diseases such as 
chronic obstructive pulmonary disease or asthma (xanthines (e.g., 
theophylline)), as these drugs are contraindicated by the nicotine patch. 
13) Participants using non-nicotine smoking cessation medications at time of 
enrollment (buproprion, varenicline). 
14) Participants who report experiencing clinically significant sexual difficulties, 
including hypoactive sexual desire disorder, sexual arousal disorder, 
premature ejaculation, or inhibited orgasm prior to the onset of smoking. 
15) Recent myocardial infarction, serious heart arrhythmias, and those with 
serious or worsening angina. 
16) Hypersensitivity or allergy to nicotine, and/or allergy to adhesive tape or 
bandages. 
17) History of or current psoriasis, dermatitis (atopic or eczematous), active 
peptic ulcers, severe renal impairment, hyperthyroidism, vasospastic 
diseases, pheochromocytoma, or insulin-dependent diabetes mellitus. 
3.3   Measures 
3.3.1   Primary outcome measures  
Physiological sexual arousal 
Penile tumescence is considered the most sensitive index of sexual arousal and the 
most reliable measure of physiological response (R. C. Rosen & Keefe, 1978). Male 
genital arousal was assessed via penile circumferential change using a mercury-in-rubber 
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strain gauge (Hokanson, Inc., Bellevue, WA, USA) positioned mid-shaft on the penis. 
The signal was sampled at a rate of 80 samples/second, low-pass filtered (to 0.5 Hz), 
digitized (40 Hz), and recorded using the software package AcqKnowledge III, Version 
3.73 (BIOPAC Systems, Inc., Santa Barbara, CA, USA) and a Model MP100WS data 
acquisition unit (BIOPAC Systems, Inc., Santa Barbara CA, USA).  
Several indices of physiological sexual arousal were calculated during each visit: 
(i) mean penile tumescence during each film segment, which was converted to magnitude 
of within-session change; (ii) within-session percent change in penile tumescence; (iii) 
maximum arousal (largest circumferential measurement during the erotic film); (iv) 
percent change in maximum arousal; (v) latency to reach maximum arousal; and (vi) rate 
of onset to maximum erection (slope). 
Self-reported sexual arousal 
Genital responses alone can provide only a partial understanding of the complex 
interplay of physiological, cognitive, and behavioral factors that are responsible for the 
processing of, and responding to, sexually-relevant cues (R Rosen & Beck, 1988; 
Wincze, Hoon, & Hoon, 1977). As such, continuous measures of self-reported sexual 
arousal responses were additionally collected. These responses were measured using a 
hand-controlled device (Rellini, McCall, Randall, & Meston, 2005) which consisted of a 
computer optical mouse mounted on a wooden track divided into seven equally spaced 
intervals, where 0 indicated neutral, and 1–7 reflected increasingly higher levels of 
feeling sexually aroused. A software program written in MatLab (The MathWorks, Inc, 
Natick, MA, USA) detected the position of the pointer with respect to the y-axis of the 
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computer’s monitor, and the signal was low-pass filtered (to 0.5 Hz), and digitized (40 
Hz). Several indices of subjective sexual arousal were calculated for each visit and 
included: (i) mean self-reported arousal during each film segment; (ii) latency to reach 
maximum arousal; and (iii) rate of onset to maximum arousal (slope). This device has 
been shown to reliably measure subjective sexual arousal in a number of studies 
conducted in men (Harte & Meston, 2008a, 2008c). 
Sexual function 
Sexual function was assessed with the International Index of Erectile Function 
(IIEF; see Appendix A) (R. C. Rosen, et al., 1997), which is the most widely used 
psychometric index of self-reported erectile function. Because this measure provides an 
ecologically valid index of sexual function in the natural environment (i.e., sexual 
intercourse with a partner during the past month versus sexual functioning via laboratory-
measured physiological responses), the IIEF was considered the primary subjective 
sexual health index in this study.  
The IIEF is a 15-item measure assessing five-factor analytically derived areas of 
male sexual functioning: erectile function, orgasmic function, sexual desire, intercourse 
satisfaction, and overall satisfaction. The measure allows for the calculation of specific 
indexes for each dimension as well as measure of overall sexual functioning (score 
ranges: erectile function: 1–30; orgasmic function: 0–10; desire: 2–10; intercourse 
satisfaction: 0–15; overall satisfaction: 2–10; total: 5–75). The IIEF has demonstrated 
acceptable internal reliability (Cronbach’s alpha values of .73 and higher), test-retest 
reliability (r = .64 to r = .84), and validity (R. C. Rosen, et al., 1997) and has been 
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standardized on a sample of healthy and sexually dysfunctional men (Cappelleri, Rosen, 
Smith, Mishra, & Osterloh, 1999). An erectile function (EF) cutoff score of less than or 
equal to 25 has been demonstrated to have sensitivity of 0.97 and specificity of 0.88 to 
detect individuals with and without erectile dysfunction (Cappelleri, et al., 1999). 
Substantial agreement has been shown between these predicted and “true” classes 
(weighted kappa 0.80) (Cappelleri, et al., 1999). The severity of ED is also classified into 
five categories: no ED (EF score 26 to 30), mild (EF score 22 to 25), mild to moderate 
(EF score 17 to 21), moderate (EF score 11 to 16), and severe (EF score 6 to 10).  
3.3.2   Cardiovascular measures  
Heart rate 
Heart rates were assessed using an Omron HEM-712C (Omron Healthcare, Inc, 
Bannockburn, IL, USA) automatic inflation digital blood pressure and pulse monitor. 
Continuous heart rates during the film sequence presentations were measured using an 
electrocardiograph with an augmented 3-limb lead site paradigm (upper right chest, lower 
left chest, right ankle) which connected to the BIOPAC MP100WS data acquisition unit. 
Blood pressure 
Systolic and diastolic blood pressures (in mm Hg) were assessed using an Omron 
HEM-712C automatic inflation digital blood pressure and pulse monitor with the cuff 
placed on each participant’s non-dominant upper arm. 
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3.3.3   Anthropometric measures 
Height and weight 
 Standing height was measured (without shoes) to the nearest 0.25 inch with a 
vertical stadiometer (Health-o-Meter, Sunbeam Products, Inc., Boca Raton, FL, USA), 
and weight was assessed to the nearest 0.1 lbs with a portable digital scale (Salter, Oak 
Brook, IL, USA). Body mass index (BMI) was calculated by diving each participant’s 
weight (converted to kilograms) by the square of his height (converted to meters).   
3.3.4   Moderating variables 
Nicotine dependence 
The Fagerstrom Test for Nicotine Dependence (FTND; see Appendix E) 
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) is a widely used 6-item 
instrument for quantifying physical nicotine dependence in smokers. The FTND has 
satisfactory internal consistency (Cronbach's a =.64) and high test-retest reliability (r = 
.88) (Heatherton, et al., 1991). Findings indicate that the FTND correlates with biological 
measures of nicotine dependence (expired-air carbon monoxide levels, plasma nicotine 
levels, plasma cotinine levels). The FTND total score has a range of 0 to 10 points, and 
can be classified into five categories: very low addiction (0 to 2 points), low addiction (3 
to 4 points), medium addiction (5 points), high addiction (6 to 7 points), and very high 





The Positive and Negative Affect Schedule (PANAS; see Appendix F) (D. 
Watson, Clark, & Tellegen, 1988) was administered to examine whether changes in 
affect in response to smoking cessation may mediate sexual arousal responses (e.g., 
increased tension and/or irritability may distract one from processing sexually relevant 
cues, resulting in decreased sexual arousal). The PANAS is a brief self-report inventory 
and consists of two 10-item mood scales which provide measures of both positive and 
negative affect. These two dimensions are dispositional, with high negative affect 
reflecting subjective distress and unpleasurable engagement with the environment, and 
high positive affect indicative of pleasurable engagement with the environment. Low 
scores within each scale represent the absence of these dimension-specific high-valence 
feelings. Thus, emotions such as enthusiasm and alertness are characteristic of high 
positive affect, while sadness is reflective of low positive affect (D Watson & Clark, 
1984).  
Participants rated the extent to which they were experiencing each particular 
emotion at that given moment on a 5-point Likert scale ranging from 1 (“very slightly or 
not at all”) to 5 (“extremely”). Scores were summed within each factor. The PANAS has 
demonstrated high internal consistency (Cronbach's alphas ranging from .84 to .90), 
acceptable test-retest reliability (r = .68 - .71) and validity (D. Watson, et al., 1988). 
When used with short-term instructions (e.g., a participant rating how he feels right now 
or today), the PANAS is sensitive to fluctuations in mood (D. Watson, et al., 1988).  
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Smoking history  
It is reasonable to believe that smoking cessation may differentially enhance 
smoker’s sexual arousal as a function of their lifetime cigarette consumption. Therefore, 
age at smoking onset, as well as the duration and frequency of cigarette consumption 
were assessed. Additionally, these data were converted to pack years, which is a term 
used to describe the amount a person has smoked over time. One pack year is defined as 
20 manufactured cigarettes (1 pack) smoked per day for one year. Irrespective of lifetime 
smoking history, a participant’s smoking frequency (cigarettes/day) at time of enrollment 
was also assessed. 
3.3.5   Protocol monitoring 
Nicotine patch compliance 
 Considering that nicotine may exert acute effects on sexual arousal in men (Harte 
2008), participants’ compliance with nicotine patch use was monitored throughout the 
study. Specifically, participants were asked on a weekly basis to report via telephone: (i) 
the frequency of patch use (number of days/week); (ii) the dose of each patch used 
(21mg, 14mg, 7mg); and (iii) the timing of each patch adherence and removal.  
Intra- and post-treatment tobacco/nicotine use  
 Participants were asked on a weekly basis to report via telephone: (i) the number 
of cigarettes smoked per day during the prior week; (ii) the number of instances of 
nicotine replacement therapy (NRT) use other than the patch (i.e., nicotine gum, nicotine 
nasal spray, nicotine lozenge, nicotine inhaler).  
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Assessment of treatment side effects 
The  Systematic Assessment for Treatment Emergent Events (SAFTEE; see 
Appendix G) (Levine & Schooler, 1986) is a rating scale designed to collect and assess 
information on patient side effects during a clinical intervention study or clinical trial. 
The SAFTEE was administered to participants at mid-treatment (while participants were 
using a 21-mg nicotine transdermal patch), and immediately after they completed their 8-
week patch regimen. 
3.3.6   Screening measures 
Alcohol use 
 Alcohol use was assessed with the Alcohol Use Disorders Identification Test 
(AUDIT; see Appendix C) (J. Saunders, et al., 1993). The AUDIT is a brief 10-item 
screening scale that assesses three conceptual domains: alcohol consumption (3 items), 
alcohol dependence (3 items), and adverse consequences of alcohol use (4 items). The 
AUDIT has demonstrated acceptable internal consistency (Cronbach's alphas above .80) 
(Allen, Litten, Fertig, & Babor, 1997; Reinert & Allen, 2002), test-retest reliability (r = 
.64 - .92) (Reinert & Allen, 2002), and acceptable validity. It has also been shown to be 
appropriate for use with people from a variety of ethnic groups (Reinert & Allen, 2002). 
Scores on the AUDIT correlate well with other self-report screening tests of alcohol use 
(e.g., CAGE, Michigan Alcohol Screening Test), and are associated with biochemical 
measures of drinking (Bohn, Babor, & Kranzler, 1995).   
Individual item scores range from 0 to 4, with the total score ranging from 0 to 40. 
Higher scores reflect increasing levels of problematic drinking. The severity of alcohol 
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use is classified into four categories: low risk (total score 0 – 7), mild/moderate risk (total 
score 8 – 15), moderate/high risk (total score 16 – 19), and very high risk (total score 20 – 
40). A cutoff score of 8 is generally used as an indication of hazardous and harmful 
alcohol use, as well as possible alcohol dependence (Allen, et al., 1997; Reinert & Allen, 
2002). For the purpose of this study, individuals with a high risk of alcohol 
abuse/dependence were precluded from entering the study, and as such, a cutoff of 16 
was used.   
Substance use 
 Substance use was assessed with the 10-item version of the Drug Abuse 
Screening Test ((DAST-10); see Appendix D) (Skinner, 1982). The DAST-10 is a brief 
face-valid self-report measure of problematic substance use other than alcohol that is 
commonly used for both research and clinical purposes. The DAST-10 has demonstrated 
acceptable internal consistency (Cronbach's alphas above .86 - .94) (Carey, Carey, & 
Chandra, 2003; Cocco & Carey, 1998), test-retest reliability (r = .71) (Cocco & Carey, 
1998), and acceptable validity (Yudko, Lozhkina, & Fouts, 2007). All items are binary 
(yes/no), each valued at one point, yielding a total score of 0 – 10. Substance abuse 
severity can be classified according to the DAST-10 total score, with 0 representing no 
drug abuse problem, 1-2 a low level problem, 3-5 a moderate problem, 6-8 a substantial 
problem, and 9-10 a severe problem. A cutoff score of 3 is typically used to distinguish 
those with substance abuse/dependence of a clinical nature (Skinner, 1982). In an attempt 
to enhance generalizability of the participant sample, only those with DAST scores 6 and 
above were precluded from entering the study.   
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3.4   Treatment 
3.4.1   Pharmacotherapy 
3.4.1.1   Rationale for nicotine transdermal patch use  
During the past 20 years, several nicotine replacement therapies (NRTs) have 
been marketed and evaluated as aids for smoking cessation including the nicotine patch, 
inhaler, nasal spray, gum, sublingual tablet, and lozenge. These treatments deliver 
nicotine systemically, providing pharmacological effects of nicotine similar to that 
obtained by smoking, and reducing physiological withdrawal symptoms (e.g., depressed 
mood, irritability, anxiety, headaches) (M. C. Fiore, Jorenby, Baker, & Kenford, 1992; 
Henningfield, 1995).   
Several meta-analyses have clearly demonstrated that, in comparison to placebo, 
NRTs help smokers quit cigarettes (Capeda-Benito, 1993; M. C. Fiore, Smith, Jorenby, & 
Baker, 1994; Silagy, Mant, Fowler, & Lodge, 1994). Although all forms of NRTs are 
efficacious, transdermal nicotine patches have a number of advantages. It has been 
estimated that the clinical efficacy of nicotine transdermal systems is 60% greater than 
nicotine chewing gum (Gore & Chien, 1998). Nicotine patches also have a number of 
pharmacokinetic advantages. Nicotine transdermal patches can deliver nicotine directly to 
the systemic circulation via intact skin, thereby avoiding “first-pass” metabolism after 
oral administration (Gore & Chien, 1998). Additionally, contrary to nicotine gum, 
lozenges, nasal spray, and the inhaler – which produce an intensive fluctuation of 
nicotine plasma peaks and troughs – nicotine patches maintain a relatively steady-state 
plasma nicotine concentration profile (Gore & Chien, 1998). Therefore, with respect to 
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measuring the physiological effects of nicotine administration, the transdermal patch 
enables a more standardized dose by precluding idiosyncratic consumption characteristics 
such as chew frequency and oral placement which alters absorption rate of nicotine.     
3.4.1.2   Clinical pharmacokinetics of the nicotine patch  
Extensive studies have been conducted in order to delineate the drug release and 
skin permeation kinetics of nicotine transdermal patches. Results of all transdermal patch 
systems reveal that the delivery of nicotine is quite fast during the first 6-8 hours, and  
 
Figure 2: Comparative Pharmacokinetic Profiles of Nicotine in Humans After Single-Dose Application of 
Nicotine Transdermal Systems (n = 11–13).  
Figure from Morgan and Cohen (1995).  
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then shifts to a lower rate of permeation at a steady state (Ho & Chien, 1993). Figure 2 
delineates the single-dose pharmacokinetic profiles of 4 nicotine transdermal patch 
systems (Morgan & Cohen, 1995). It can be seen that three distinct phases exist: incline 
phase; plateau phase, which has a fairly steady plasma nicotine level; and decline phase, 
which follows the removal of the patch system. The administration of one patch, 
irrespective of brand, raises plasma nicotine concentration level to approximately 15µg/L. 
When a second nicotine patch is applied to a new skin site (after the removal of the initial 
patch), the gradual rise in nicotine levels during the incline phase overlaps with the 
declining plasma profile of the original patch, thus maintaining a virtually constant 
plasma  concentration (Berner, 1992), without accumulation of nicotine over contiguous 
doses (Ross, Chan, Piraino, & John, 1991).  
The pharmacokinetics of nicotine delivery via the transdermal patch is quite 
different from other delivery methods. As seen in Figure 3, nicotine nasal spray takes 
between 5 and 10 minutes to reach peak (Russell, Jarvis, Feyerabend, & Ferno, 1983), 
demonstrating a similar rate of action as smoking cigarettes (Benowitz, Porchet, Sheiner, 
& Jacob, 1988). However, plasma levels of nicotine delivered nasally drop rapidly, 
yielding a highly fluctuating profile. Nicotine gum produces a more stable plasma profile; 
however peak plasma concentration is lower compared to other NRTs (Tutka, 
Mosiewicz, & Wielosz, 2005), and many patients report gastrointestinal upset 
(Henningfield, 1995).  
Considering the literature supporting nicotine patch efficacy and tolerability, as 
well as the ease of use (administered once per day compared to ad lib), I believed that 
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administering the nicotine patch, compared to other NRTs, would produce the highest 
abstinence rates.   
 
 
Figure 3. Comparative Pharmacokinetic Profiles of Nicotine from Different Nicotine Products. 
Keys: ( ) Cigarette (1.97 mg); ( ) Nasal spray (2-mg dose); ( ) Nicorette® chewing gum (2-mg dose). 
Nicotine: 1 nmol/L ≈ 0.16 ng/mL. Modified from Russell et al. (1983). 
 
3.4.1.3   Nicotine patch dose and regimen 
Participants were given an 8-week nicotine transdermal patch treatment 
(Habitrol®, Novartis Consumer Health Inc., Summit, NJ, USA) administered in a step-
down fashion (21-mg, weeks 1-4; 14-mg, weeks 5-6; 7-mg, weeks 7-8). The patch was 
applied once daily, usually at the same time each day (typically upon wakening), and was 
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worn continuously for 24 hours. The 21-mg patch was administered at the beginning of 
treatment because this dose is the most appropriate for heavy smokers (>15 
cigarettes/day). Changes in treatment length (extension or reduction) at the request of a 
participant were permitted. In cases where enrolled participants reported (at their initial 
visit) smoking less than the minimum requirement (15 cigarettes/day), treatment 
regimens were tailored accordingly, under the supervision of a consulting pharmacist.    
3.4.2   Adjunctive counseling 
3.4.2.1   Overview of adjunctive counseling 
Research indicates that combining in-person and/or telephone counseling with 
NRT significantly enhances quit rates (M. Fiore, et al., 2000; Macleod, Charles, Arnaldi, 
& Adams, 2003). Adjunctive counseling may enhance smoking cessation medications by 
helping smokers understand NRTs with respect to their limitations, mechanisms of 
action, safe use, and adjustment to medication termination (M. Fiore, et al., 2000; 
Perkins, Conklin, & Levine, 2007). Counseling also can serve as an important 
reinforcement of a smoker’s motivation for quitting, thereby reducing relapse.  
3.4.2.2   Adjunctive counseling components 
Individual counseling was developed based upon the tobacco use and dependence 
clinical practice guidelines (M. Fiore, et al., 2000) and the protocols of the National 
Cancer Institute (Glynn & Manley, 1990). Individual counseling was intensive and 
emphasized brief assessment, psycho-education, behavioral modification, and cognitive 
intervention. Assessment included examining a participant’s level of motivation and 
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confidence to quit, reasons for quitting, current nicotine dependence level, daily smoking 
patterns (overall frequency, location, time-specific intake patterns), and triggers/cues for 
smoking. Psycho-education entailed discussing the medical risks of continued smoking, 
medical consequences of fading cigarette intake versus complete cessation, the 
relationship between smoking and weight/diet, positive predictors of smoking success, 
physiological and psychological aspects of nicotine dependence, and rationale for and 
education on the safe use of the nicotine transdermal patch. Several behavioral 
interventions were utilized such as self-monitoring, trigger reduction (removal of 
smoking related cues such as ashtrays, lighters, empty cigarette boxes, and specific 
environments), changing daily routines, increasing exercise and sleep, nutritional 
recommendations, and progressive muscle relaxation techniques. Cognitive interventions 
included identifying and altering maladaptive beliefs regarding cigarette smoking.   
3.4.2.3   Adjunctive counseling duration and frequency 
The first in-person counseling session, which occurred during a participant’s first 
visit to the laboratory, lasted 45 minutes. The second in-person counseling session lasted 
30 minutes and occurred during the second experimental session. Handouts were given 
which entailed many of the psycho-education components described above. Participants 
also received a minimum of 10 weekly telephone counseling sessions each lasting 10 
minutes in duration. These phone sessions targeted topics that were relevant to the 
individual’s place in the quitting process. In-person counseling interventions were 
conducted by a trained psychology graduate student. Telephone counseling was 
performed by a trained research assistant supervised by the primary investigator.  
 44
3.5 Procedure  
3.5.1   Overview of procedure 
Prospective study participants were screened by telephone to determine their 
eligibility to enter the study (see Section 3.2.2 detailing inclusion/exclusion criteria). 
Eligible participants were asked to abstain from caffeine and alcohol for 2 hours prior to 
each experimental condition. During the initial telephone screening, a quit date was set, 
which corresponded to the day after their first experimental session. Participants were 
asked to not reduce their smoking frequency from the time of initial screening to the time 
of their first appointment, as research indicates no differential treatment outcome in 
successful cessation as a function of smoking as usual versus cutting down on cigarette 
intake prior to nicotine replacement therapy use (Günther, Gritsch, & Meise, 1992; 
Hughes, 2000). Additionally, it was important for participants to smoke as usual leading 
up to their first session in order to ensure an accurate assessment of baseline sexual 
functioning.  
Participants were not asked to refrain from smoking during the day of their initial 
assessment, and therefore they entered the laboratory at their preferred nicotine level. 
This was in order to rule out confounding effects of withdrawal symptoms on sexual 
functioning. Additionally, participants were not allowed to smoke during any 
experimental session. Considering that acute nicotine intake significantly inhibits sexual 
arousal in nonsmokers (Harte & Meston, 2008a), it may be possible that smoking-
induced ED is largely a result of acute deleterious effects of nicotine and/or tobacco 
smoke on sexual function, irrespective of smoking history. I believed that having 
 45
participants smoke prior to entering the laboratory (corresponding to approximately 1 
hour from nicotine administration to physiological assessment of sexual arousal) would 
enable a more accurate assessment of “baseline” erectile functioning, thereby precluding 
withdrawal effects and nicotine-induced acute effects.   
All participants were tested individually while seated in a comfortable armchair 
within a dimly lighted private, internally locked testing room with a television monitor 
approximately 10 feet away. An intercom system between the participant and the 
experimenter rooms allowed for communication with participants at all times. Only a 
male experimenter tested male participants. The protocol was approved by the University 
of Texas at Austin Institutional Review Board.  
3.5.2   Procedure 
Visit 1 – Pre-treatment (baseline assessment while smoking)  
 The researcher explained the experimental procedure and showed the participant 
the laboratory and the measurement devices used to assess subjective and physiological 
sexual arousal. Participants then read a consent form, which contained information with 
respect to the nature, purpose, potential risks, and contact information for individuals 
responsible for the study. The informed consent also included specific information about 
how data would be kept confidential, the safety of the physiological equipment, and the 
general study procedure. Participants were asked to sign one copy for the researcher’s 
records, and keep another copy for their records. Each participant was also asked to sign 
a contract stating that he was committed to completing all experimental sessions, 
regardless of his smoking status.  
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Visit Number 1 2 * 3
Study Day Screening 1 8 15 22 29 36 43 50 57 64 71 78 85
Screening Measures
      Alcohol Use (DAST) X X
      Susbstance Use (AUDIT) X X
      Kinsey Sexual Orientation Scale X
      Smoking History X X
      Medical History X X
Primary Outcome Measures
      Physiological sexual arousal X X X
      Continuous self-reported sexual arousal X X X
      Self-reported sexual functioning (IIEF) X X X
Cardiovascular Measures
      Blood pressure X X X
      Heart rate X X X
Anthropomorphic Measures
      Height X X
      Weight X X X
Moderating Variables
      Affect  (PANAS) X X X
      Nicotine Dependence (FTND) X
      Nicotine patch compliance** X X X X X X X X X X X X
      Intra- and post-treatment tobacco use** X X X X X X X X X X X X
Safety Determinations
  SAFTEE X X
Table 3. Time Events Chart Listing all Measures and Occasions for their Administration.  
Abbreviations: AUDIT = Alcohol Use Disorders Identification Test; DAST-10 = Drug Abuse Screening Test, 10-item version; FTND = Fagerström Test of 
Nicotine Dependence; IIEF = International Index of Erectile Functioning; PANAS = Positive and Negative Affect Schedule; SAFTEE = Systematic Assessment for 
Treatment Emergent Events. 
*The SAFTEE was administered via telephone, thereby precluding a visit to the laboratory. 
**Nicotine patch compliance, as well as smoking and/or NRT use during patch treatment and post-treatment, was assessed via telephone.  
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         After giving consent, the participant’s height and weight were measured, and his 
heart rate and systolic and diastolic blood pressures were assessed. Participants were then 
questioned on their smoking history and current smoking patterns. They were then asked 
to complete a battery of questionnaires in privacy (see Table 3 for a detailed time events 
chart listing the measures and occasions for their administration). Participants also 
provided a saliva sample and they were spuriously informed that all samples would be 
assayed for salivary nicotine content. This was to help ensure valid self-reporting of 
cigarette consumption.  
 After participants completed the survey packet, they were instructed on how to fit 
the penile plethysmograph, and how to use the subjective sexual arousal device. The 
electrocardiograph leads were also attached. Participants were then randomized to view 1 
of 3 films. All visual presentations started with word “relax” presented on the screen for 1 
minute. This was followed by a nonsexual neutral segment (3 minutes consisting of a 
documentary film) after which an erotic video segment (8 minutes consisting of a 
heterosexual couple engaging in petting, oral sex, and sexual intercourse) was 
immediately presented. These films have previously been shown to reliably elicit 
physiological and subjective sexual arousal in men (Harte & Meston, 2008a). The 
sequences of films differed only in the content of the neutral and erotic films, and these 
films were counterbalanced across subjects. During film presentation, participants were 
asked to continuously monitor their level of subjective sexual arousal using a hand-
controlled device positioned to the side of the chair in which they were seated.  
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 Immediately following the erotic film, participants were instructed via the 
intercom system to remove the plethysmograph and remove the electrocardiograph leads. 
Participants were given 28 high dose patches (21-mg, 24-hour release; to be worn once 
daily for 4 weeks), and were asked to start nicotine replacement therapy the following 
morning. Participants were given detailed instructions on proper and safe use of the 
patch, and were also given handouts which included information on how to maximize 
their smoking cessation effectiveness. Finally, participants received cognitive-behavioral 
counseling, and weekly 10-minute phone counseling sessions were scheduled. The entire 
session lasted 2 hours.  
Visit 2 – Treatment (assessment while using the nicotine transdermal patch) 
Participants returned to the laboratory for their second visit, during the fourth 
week of their 21-mg nicotine transdermal patch treatment. The test session was identical 
to visit 1 described above, with the exception that they will not be assessed 
anthropometrically (see Table 3). Pharmacotherapy-related side effects were assessed, 
and participants were given fourteen 14-mg patches (24-hour release; to be worn once per 
day for 2 weeks), and fourteen 7-mg patches (24-hour release; to be worn once per day 
for 2 weeks) to be used for the remaining 4 weeks of pharmacotherapy. Participants were 
asked to start the 14-mg patch the following morning after they were finished with their 
last 21-mg patch. Participants continued to be contacted once weekly to assess patch 
compliance and intra-treatment tobacco use, as well as participate in 10-minute phone 
counseling. The entire session lasted 1.5 hours.  
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End-treatment safety check 
 Side effects during weeks 5 through 8 of the nicotine patch regimen were assessed 
again at the completion of the patch treatment via telephone. Participants continued to be 
contacted once weekly for 10-minute phone counseling sessions. 
Visit 3 – Follow-up (4 week post-treatment assessment) 
Four weeks after cessation of the nicotine patch, participants were reevaluated. 
Specifically, their height and weight were reassessed, as well as their self-report measures 
of sexual functioning and mood (see Table 3). Participants again provided saliva samples, 
and were assessed psychophysiologically as described in visits 1 and 2. Participants were 
debriefed and given an opportunity to ask any questions relating to the study. They were 
then provided $30 in cash for study completion, and were mailed a detailed report (see 
Appendix H) of their laboratory assessments within one week. The session lasted 1 hour.  
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CHAPTER 4: DATA ANALYSIS 
4.1 Data reduction  
With respect to physiological sexual arousal, movement artifacts—defined as 
clear spikes >5 mm within an otherwise smooth curve (George, et al., 2006)—were 
deleted. The remaining raw data were digitally transformed into millimeters of 
circumference change. Initial physiological and continuous subjective sexual arousal 
scores for each session were computed by averaging all data points within 10-second 
epochs, and then all epochs within the neutral (18 epochs) and erotic films (48 epochs) 
were separately averaged. For physiological sexual arousal, change scores were 
calculated by subtracting the mean during the neutral film from the mean during the 
erotic film. Percent change (from the neutral film to the erotic film) was calculated for 
both physiological and continuous subjective sexual arousal. Heart rates during the film 
presentation were averaged across the neutral and erotic films, yielding a total of three 
heart rate measures (one prior to the film sequence, and two during the film sequence) for 
each participant per experimental condition. With respect to self-reported sexual function, 
participants reporting an erectile function score of less than or equal to 25 were 
considered to be experiencing erectile dysfunction of a clinical nature.  
4.2   Defining treatment outcome groups 
 Efficacy of smoking cessation was evaluated with the use of a 1-week point 
prevalence abstinence rate at follow-up (week 12). Participants were classified as being 
totally abstinent if they reported smoking zero cigarettes during the previous seven days, 
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whereas individuals reporting smoking 1-20 cigarettes during the prior seven days were 
classified as being partially abstinent. Men smoking more than 20 cigarettes were 
considered relapsed. Because there were no differences between completely and partially 
abstinent men for any of the outcome measures (all ps > .05), these groups were 
combined for the initial analyses involving the subgroup of successful quitters only.  
 For the intent-to-treat (ITT) analyses, which included all participants, a more 
stringent classification was adopted: participants reporting zero cigarettes during the prior 
7 days at follow-up were considered successful quitters, whereas individuals reporting 1 
or more cigarettes were classified as unsuccessful quitters (relapsers). With respect to 
treatment efficacy data, the above stringent classification was used.    
4.3   Statistical analyses  
4.3.1   Overview 
All dependent variables were checked for normality using Shapiro–Wilk tests 
with an alpha of p < .05 denoting a normality violation. Variables that were not normally 
distributed were log transformed. All analyses were performed using SPSS statistical 
software version 18.0 (SPSS Inc., Chicago, IL, USA). A two-tailed alpha of p < .05 was 
considered statistically significant for all analyses. Effect sizes (i.e., Cohen’s d, Pearson r, 
Cramér’s φ) were reported when comparing two groups. Measures of variance, such as η2 
and R2, were reported when comparing more than two groups and magnitude of 
association, respectively. All variances and effect sizes were calculated according to the 
guidelines proposed by Cohen (1988).  
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4.3.2   Statistical power considerations 
A priori power analyses for a 3 (experimental session) × 2 (group: successful 
quitter vs. relapser) repeated measures analysis of variance (ANOVA) design, with a 
moderate effect size (f = .32) and a two-tailed alpha set at .05, suggested that 18 
participants in each group were necessary at each time point in order to have power of 
0.80 to detect group-specific across-session differences. The a priori effect size of .32 
was taken from a previous study (Harte & Meston, 2008a) examining acute effects of 
nicotine administration on sexual arousal using the same methods and instrumentation as 
the proposed study. Additionally, a priori power analyses indicated that a total sample 
size of 54 participants was necessary in order to adequately assess between-group 
differences. To ensure sufficient power, 65 participants were enrolled.  
4.3.3   Handling missing data 
 All initial analyses were conducted on the subgroup of successful quitters only 
(complete abstainers and partial abstainers combined). Across-session changes were 
assessed using list-wise deletion, as well as with the traditional last observation carried 
forward (LOCF) technique, and full information maximum likelihood (FIML) estimation 
(Little & Rubin, 2002). The FIML approach was used with the expectation maximization 
(EM) algorithm, which estimates missing values iteratively by case-wise maximizing the 
likelihood of the observed data in the dataset (Wothke, 2000). This technique was 
employed because this approach produces more accurate parameter estimates than list-
wise deletion and LOCF (Enders, 2001; Enders & Bandalos, 2001; J.L. Schafer & 
Graham, 2002).  
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Additionally, ITT analyses were conducted for all participants (successful quitters 
and relapsers) using FIML. Missing values (for session 2 and 3) for each primary 
outcome variables were successively estimated using several characteristics as predictors 
such as age, pack years, baseline smoking frequency, erectile dysfunction status, drug and 
alcohol severity, dropout status, as well as each corresponding baseline primary outcome 
value. Additionally, the total number of cigarettes smoked throughout the study, the total 
number of days a participant wore the patch, and the number of cigarettes smoked during 
week 12 were estimated in a similar fashion. For the ITT analyses, group status 
(successful quitter, relapser) was based on these imputed values.  
4.3.4   Tests of potential confounding variables 
For the initial analyses on the subgroup of successful quitters, potential 
demographic (age, pack years), physical (BMI, flaccid penile circumference*), clinical 
(erectile functioning as per the IIEF, alcohol and substance use), and protocol-related 
(total cigarettes smoked during study, total days of patch use) confounding variables were 
entered into a stepwise multiple regression analysis for each outcome variable for each 
type of missing data approach (i.e., list-wise deletion, LOCF, FIML). For the list-wise 
approach, the only variable that reached significance was total cigarettes smoked 
throughout the study with respect to the intercourse satisfaction subscale of the IIEF (p < 
.01). For LOCF and FIML, total cigarettes smoked throughout the study, age, and pack 
years were entered as covariates in all analyses.   
                                                 
*This was entered as a possible covariate because differences in individual flaccid penis size cause 
differential circumferential changes during sexual arousal (Jamison & Gebhard, 1988). 
 54
For the ITT analyses, pack years, total cigarettes smoked throughout enrollment, 
baseline erectile functioning, baseline drinking severity, and smoking status at visit 2 
(smoke-free, relapsed) were entered as covariates in all analyses.  
4.3.5   Validity check for the audiovisual manipulation 
 In order to ensure that the erotic stimuli facilitated sexual arousal, two separate 2 
(Film segment: neutral vs. erotic) × 3 (Film sequence (i.e., which of the 3 erotic films 
were shown during the first experimental session)) repeated measures ANOVAs were 
conducted with both physiological sexual arousal and continuous self-reported sexual 
arousal as dependent measures. There was an overall main effect of film for both 
physiological (F(1,62) = 98.04, p < .001, η2 = .61) and self-reported (F(1,62) = 381.51, p 
< .001, η2 = .86) sexual arousal, indicating that the audiovisual stimuli were sufficient to 
elicit reliable sexual arousal responses. The lack of a film segment by film sequence 
interaction for either physiological (p = .97) or subjective (p = .65) sexual arousal 
indicated that all films induced sexual arousal to a similar degree.    
4.3.6   Tests of major study hypotheses  
Aim 1: To investigate within- and between-group changes in physiological sexual 
arousal. Separate repeated measures ANCOVAs, with time (baseline, pre-treatment, 
follow-up) as a within-subjects factor, were performed on each of the physiological 
sexual arousal indices (raw change and percent increase in penile tumescence, maximum 
arousal, percent change to maximum arousal, latency to maximum arousal, and slope to 
maximum erection) among successful quitters. Greenhouse-Geisser corrected 
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significance values were reported when the sphericity assumption was not met. Planned 
comparison paired sample t-tests for adjusted cell means were used to assess across-
session differences.  
With respect to the ITT analyses, general linear modeling was used as the primary 
analytic approach to compare the two groups at each time point for all outcome measures. 
Specifically, a series of univariate 3×2 repeated measures ANCOVA models were 
employed. This approach enabled the modeling of outcome measures as a function of 
time of assessment (within subjects), treatment effects (between subjects), and covariate 
characteristics. For these analyses, the interaction effect of treatment×time was of 
primary interest. In cases where the overall interaction term was statistically significant, 
planned comparison F-tests for adjusted cell means were used to assess between-group 
differences at each time point.  
Aim 2: To investigate within- and between-group changes in continuous 
subjective sexual arousal. Analyses were similar to those used in Aim 1, with repeated 
measures ANCOVAs, with time as a within-subjects factor, performed on each of the 
continuous subjective sexual arousal variables (percent change in sexual arousal, latency 
to maximum arousal, and slope to maximum arousal) among successful quitters. Planned 
comparison paired sample t-tests for adjusted cell means were used to assess across-
session differences. Intention-to-treat analyses were conducted similar to those in Aim 1. 
Aim 3: To investigate within- and between-group changes in self-reported sexual 
function. Analyses were similar to those used in Aims 1 and 2, with repeated measures 
ANCOVAs, with time as a within-subjects factor, performed on 6 of 7 sexual function 
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variables (erectile function, orgasmic function, sexual desire, intercourse satisfaction, 
overall satisfaction, and overall sexual functioning) among successful quitters. Paired 
sample t-tests for adjusted cell means were used to assess across-session differences. To 
examine across-session changes in proportion of men with ED, Pearson χ2 tests were 
used.  
Analyses on the intent-to-treat sample were conducted similar to those in Aim 1. 
Additionally, multivariate logistic regression analyses were used to examine the 
association between quitting smoking and erectile dysfunction status at mid-treatment 
and follow-up. Variables were examined using the Wald test and adjusted odds ratios 
with their 95%confidence intervals were calculated. 
4.3.7   Tests of moderator hypotheses 
Whether subjective ratings of affect covaried with the three outcome measures 
(physiological sexual arousal, continuous self-reported sexual arousal, self-reported 
sexual function) were explored for both successful quitters and unsuccessful quitters 
separately. Difference scores between the first and last session were separately derived 
within participants for each outcome measure, as well as for positive and negative affect 
scores. These sets of difference scores were then entered into separate regression models.  
4.3.8   Additional analyses 
A series of 3 (session: baseline, pre-treatment, follow-up) ×2 (group: successful 
quitter, unsuccessful quitter) repeated measures ANCOVA models were employed to 
examine the effects of smoking cessation on systolic and diastolic blood pressure scores, 
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and on BMI. Resting heart rates were analyzed with a 3 (session: baseline, pre-treatment, 
follow-up) × 2 (group: successful quitter, unsuccessful quitter) repeated measures 
ANOVA. In the case where the overall interaction term was statistically significant, 
planned comparison F-tests for adjusted cell means were used to assess between-group 
differences at each time point. 
Differences in baseline characteristics between treatment completers and 
dropouts, as well as between successful and unsuccessful quitters, were compared with t 
tests or Pearson χ2 tests, as appropriate. Fisher’s Exact tests were used in cases with low 
cell counts. A Pearson product moment correlation coefficient was used to quantify the 
relation between physiological and continuous self-reported sexual arousal for each 
experimental session.  
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CHAPTER 5: RESULTS 
5.1 Participant characteristics 
 Two hundred twenty-eight men completed the initial telephone screening. Of 
these individuals, 116 were ineligible, 9 declined to participate, and 9 were unable to be 
contacted further in order to enroll. Of the 112 men who met inclusion criteria, 47 did not 
show for their initial evaluation, resulting in a final sample of 65 participants. The 
dropout rate was 28% after the initial visit, and 49% after the second visit, resulting in 
51% who completed the study (see Figure 4 for participant flow).  
 The total sample had a mean age of 39 years (SD = 10.76; range, 23-58), was 
predominantly White (86%), reported an average of 15 years of education (SD = 2.23; 
range, 12-22), and reported a mean of approximately 22 pack-years (SD = 16.17; range, 
2-77). Participants reported a mean age of smoking onset of 17 years (SD = 4.56; range, 
8-40), and were smoking an average of 22 cigarettes per day (SD = 7.89; range, 12-40), 
and were highly addicted to tobacco (FTND total score = 5.45; SD = 1.97; range 1-10). 
The sample had a mean IIEF erectile function score and a mean IIEF total score of 26.7 
(SD = 4.88; range, 2-30) and 62.3 (SD = 10.15; range, 20-75), respectively, and 
approximately 29% of these participants had ED according to IIEF established standards. 
Mean scores for other domains of sexual functioning as per the IIEF were as follows: 
orgasmic function (M = 9.0; SD = 1.48), sexual desire (M = 7.2; SD = 1.69), intercourse 
satisfaction (M = 11.7; SD = 2.81), and overall satisfaction (M = 7.7; SD = 1.89). 
Seventeen men reported taking medications, the majority of which were allergy related. 
Characteristics of the participant sample are presented in Table 4. 
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45 Successful Quitters 




















                                                                         
 
    
228 Assessed for eligibility 
112 Scheduled for baseline assessment 
     65 Received baseline evaluation 
     47 Did not receive baseline evaluation: 
     40 Lost to follow-up 
     3   Declined to participate further 
     1   Relocated 
     3   Time conflict 
116 Excluded 
     98 Did not meet inclusion criteria: 
          49 Insufficient baseline smoking 
          24 Medical conditions/medications 
          12 Excessive alcohol/substance use 
          8   Sexual transmitted infection 
          5   Other reason 
     9 Declined participation 
     9 Unable to locate in order to enroll 
47 Received mid-treatment evaluation 
     18 Did not receive evaluation: 
     17 Lost to follow-up 
     1   Relocated 
33 Received follow-up evaluation 
     14 Did not receive evaluation: 
     11 Lost to follow-up 
     1   Relocated 
     2   Time conflict 
65 Included in final analysis 
0   Excluded from analysis 





Successful quitters (n = 20)  Unsuccessful quitters (n = 45)    
Mean (SD) n (%)  Mean (SD) n (%)  P value 
Demographics            
      Age (years)* 34.9 (9.65)    40.4 (10.9)    .06 
      Education (years)† 15.5 (2.04)    14.4 (2.25)    .07 
      Ethnicity             
          White   19 (95.0)    37 (82.2)    
          African-American   0 (0.0)    3 (6.7)    
          Latino/a   0 (0.0)    3 (6.7)  .19 
          Asian   0 (0.0)    2 (4.4)    
          Other   1 (5.0)    0 (0.0)    
      Income (US dollars)             
          < 25,000   6 (30.0)     7 (15.6)    
          25,000 - 49,999   6 (30.0)     18 (40.0)    
          50,000 - 74,999   6 (30.0)     9 (20.0)  .45 
          75,000 - 99,000   2 (10.0)     6 (13.3)    
          ≥ 100,000   0 (0.0)     5 (11.1)    
      Marital status             
          Single   12 (60.0)    15 (33.3)    
          Married   4 (20.0)    18 (40.0)    
          Common Law   1 (5.0)    3 (6.7)  .53 
          Divorced   3 (15.0)    8 (17.8)    
          Widowed   0 (0.0)    1 (2.2)    
      BMI (kg/m2) 25.9 (3.67)    26.2 (4.81)    .80 
Screening measures             
      AUDIT score 6.9 (3.13)    4.1 (3.18)    <.01 
      DAST-10 score .7 (.98)    .6 (.78)    .66 
 
Table 4. Demographics of the Participant Sample. 
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Characteristic 
Successful quitters   Unsuccessful quitters    
Mean (SD) n (%)   Mean (SD) n (%)  P value 
Smoking characteristics              
      Age of onset (years)* 16.1 (2.37)     16.8 (5.3)    .57 
      Smoking duration (years)* 17.9 (10.03)     22.6 (11.4)    .12 
      Pack years 18.2 (14.02)     23.1 (16.9)    .26 
      Current smoking frequency (cigs/day)* 19.0 (5.09)     22.8 (8.66)    .07 
      Nicotine dependence*‡ 5.4 (1.84)     5.5 (2.04)    .78 
      Number of quit attempts* 3.4 (2.78)     3.5 (2.66)    .81 
      Smoking partner¥   6 (30.0)     17 (39.5)  .46 
      Motivation level to quit smoking* 8.4 (1.09)     8.5 (1.11)    .70 
      Confidence level to quit smoking* 7.3 (1.52)     7.5 (1.93)    .68 
Sexual functioning¶               
      Erectile function 27.0 (4.75)     26.5 (5.19)    .72 
      Orgasmic function 8.7 (1.87)     9.0 (1.42)    .45 
      Sexual desire 6.8 (1.52)     7.4 (1.74)    .13 
      Intercourse satisfaction 11.9 (2.13)     11.6 (3.08)    .67 
      Overall satisfaction 7.9 (1.76)     7.6 (1.95)    .63 
      Overall sexual functioning (total score) 62.2 (9.97)     62.2 (10.60)    .99 
      Erectile dysfunction**   4 (20.0)     15 (33.3)  .28 
 
    Table 4 (cont). Demographics of the Participant Sample. 
Abbreviations: AUDIT= Alcohol Use Disorders Identification Test; BMI = Body mass index; DAST-10 = Drug Abuse Screening Test, 10-item 
version. 
*Data were missing for 1 participant. 
†Data were missing for 3 participants. 
‡As per the Fagerström Test of Nicotine Dependence. 
¥ Data were missing for 2 participants. 
¶Measured on a scale from 0-10, with higher numbers representing higher levels of motivation/confidence. 
**As per the International Index of Erectile Functioning (IIEF). 
***According to the IIEF erectile functioning cutoff score of 25
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 The two subgroups of smokers did not differ significantly on the majority of 
socio-demographic and smoking characteristics, with the exception of age, education, and 
current smoking frequency. Specifically, unsuccessful quitters showed a statistical trend 
toward fewer years of education (t(63) = 1.87, p = .07; d = .23), increased age (t(63) = 
1.95, p = .06; d = .24), and higher number of cigarettes smoked daily (t(63) = 1.83, p = 
.07; d = .23). The only other variable on which groups differed was baseline drinking 
severity, with unsuccessful quitters reporting significantly less alcohol use compared to 
successful quitters (t(63) = 3.24, p < .01; d = .40). 
 Analyses comparing treatment completers and dropouts revealed that these groups 
did not differ with respect to baseline measures of alcohol and substance use, sexual 
functioning, smoking and nicotine dependence, or motivation and confidence levels 
regarding quitting. The only variables that distinguished completers and dropouts were 
education and race. Specifically, those who dropped out reported less years of education 
(t(60) = 2.34, p = .02; d = .60), and were more likely to be non-White (χ2(1) = 6.57, p = 
.01; φ = .32). No other demographic characteristics distinguished between completers and 
dropouts (all ps > .05).     
5.2   Treatment efficacy 
 Of the 65 men enrolled in the study, 7 reported relatively low nicotine dependence 
and required a non-standardized patch-treatment plan. Of these individuals, 6 received 
the 14-mg patch for 4 weeks followed by 4 weeks of the 7-mg patch, while 1 individual 
received 6 weeks of the 7-mg patch only. All other men received the standard treatment 
regimen.  
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 Thirty-five percent (23 of 65) and 69 percent (45 of 65) of men were considered 
relapsed at mid-treatment and follow-up, respectively. The total sample of participants 
reported wearing the patch an average of 29 days and reported smoking an average of 
281 cigarettes throughout the 12-week study. Successful quitters, compared to those that 
relapsed, reported smoking significantly less cigarettes (t(63) = -6.45, p < .001; d = .80) 
and reported a significantly higher number of days using the patch (t(63) = 1.97, p = .05; 
d = .27). Seven men reported supplementing the patch with other forms of NRT (nicotine 
gum, n = 4; nicotine lozenge, n = 3). The mean number of non-patch NRT usages was 55 
(SD = 55.95; range, 1-140).  
 Adverse events were rare and occurred in 29% of participants while using the 21-
mg patch and in 7% of participants toward the end of treatment (while using the 7-mg 
patch). On average, participants reported a total of .6 adverse events at mid-treatment and 
.2 adverse events at end-treatment. These included headache (n = 2), dizziness (n = 1), 
insomnia (n = 3), and itching (n = 7), and a rash (n = 2). All symptoms were reported as 
being minimal to mild in severity, and no adverse events affected the course of nicotine 
patch treatment.  
5.3   Results of major study hypotheses among the subgroup of successful quitters 
5.3.1   Analyses of physiological sexual arousal 
 With respect to participants that produced reliable physiological sexual arousal 
responses (n = 21), there were significant across-session differences for all six 
physiological sexual arousal outcome variables. Specifically, there was a significant main 
effect of time for raw change in erectile tumescence (F(2,40) = 4.61, p = .02, η2 = .19) 
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(see Figure 5), percent change in penile tumescence (F(2,40) = 3.13, p = .05, η2 = .12) 
(see Figure 6), raw change in maximum erectile response (F(2,40) = 6.14, p < .01, η2 = 
.24) (see Figure 7), percent change in maximum erectile response (F(2,40) = 8.60, p = 
.001, η2 = .26) (see Figure 8), latency to reach maximum arousal (F(2,40) = 5.69, p = .01, 
η2 = .22) (see Figure 9), and rate of onset to maximum erection (F(2,40) = 6.35, p = .01, 


































Figure 5. Raw Changes in Erectile Tumescence for Successful Quitters as a Function of Time.  
Bars represent mean within-session erectile tumescence change scores (mean tumescence during erotic stimulus 
minus mean tumescence during neutral stimulus). Error bars represent standard errors of the means. Bars without 
common superscripts are statistically different from one another (p < .05). 
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Figure 7. Raw Changes in Maximum Erectile Response for Successful Quitters as a Function of Time.  
Bars represent mean maximum erectile tumescence scores. Error bars represent standard errors of the means. Bars 
without common superscripts are statistically different from one another (p < .05). 
Figure 6. Percent Changes in Erectile Tumescence for Successful Quitters as a Function of Time.  
Bars represent mean within-session erectile tumescence percent change scores (mean tumescence during erotic 
stimulus minus mean tumescence during neutral stimulus divided by mean tumescence during neutral stimulus). 
Error bars represent standard errors of the means. Bars without common superscripts are statistically different 








































































Figure 9. Latency to Reach Maximum Erection for Successful Quitters as a Function of Time.  
Bars represent mean latencies to reach maximum erectile response. Error bars represent standard errors of the 
means. Bars without common superscripts are statistically different from one another (p < .05). 
Figure 8. Percent Changes in Maximum Erectile Response for Successful Quitters as a Function of Time.  
Bars represent mean within-session percent changes in maximum erectile tumescence scores (maximum tumescence 
during erotic stimulus minus mean tumescence during neutral stimulus divided by mean tumescence during neutral 
stimulus). Error bars represent standard errors of the means. Bars without common superscripts are statistically 


























































































































More detailed examination of the data revealed that participants exhibited greater 
within-session erectile response (t(20) = 2.73, p = .01, d = .60) (16 of 21 men), greater 
maximum tumescence (t(20) = 3.03, p = .01, d = .66) (17 of 21 men), lower latency to 
reach maximum tumescence (t(20) = 2.65, p = .02, d = .58) (16 of 21 men), and faster  
erectile onset (t(20) = 2.98, p = .01, d = .65) (20 of 21 men), at mid-treatment compared 
to baseline. This corresponded to a 43%, 4%, and 106% increase in erectile response, 
maximum tumescence, and rate of onset, respectively, and a 30% reduction in time to 
reach maximum erection. There were no differences between baseline and mid-treatment 
Figure10. Rate of Onset to Reach Maximum Erection for Successful Quitters as a Function of Time.  
Bars represent mean slope values to reach maximum erectile response. Error bars represent standard errors of the 
means. Bars without common superscripts are statistically different from one another (p < .05). 
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with respect to percent change in penile tumescence (t(20) = 1.35, p = .19, d = .29), or 
percent change in maximum tumescence (t(20) = 1.81, p = .09, d = .38).  
All six indices were also improved at follow-up compared to baseline (raw change 
in erectile tumescence (t(20) = 2.40, p = .03, d = .52) (16 of 21 men); percent change in 
erectile tumescence (t(20) = 2.27, p = .03, d = .45) (16 of 21 men), raw change in 
maximum tumescence (t(20) = 2.67, p = .02, d = .58) (15 of 21 men); percent change in 
maximum tumescence (t(20) = 3.69, p = .001, d = .74) (15 of 21 men); latency to reach 
maximum tumescence (t(20) = 2.58, p = .02, d = .56) (16 of 21 men); and erectile onset 
(t(20) = 2.68, p = .02, d = .58) (20 of 21 men)). Participants showed a 44%, 40%, 5%, 
48%, and 174% increase in raw change in erectile response, percent change in erectile 
tumescence, raw change in maximum tumescence, percent change in maximum 
tumescence, and rate of onset, respectively. Participants showed a 31% reduction in 
latency to reach maximum erection.   
There was no difference between mid-treatment and follow-up with respect to any 
of the physiological sexual arousal variables (raw change in erectile tumescence (t(20) = 
.07, p = .94, d = .02); percent change in erectile tumescence (t(20) = .07, p = .95, d = .01); 
maximum tumescence (t(20) = .17, p = .87, d = .04); percent change in maximum 
tumescence (t(20) = 1.07, p = .30, d = .23); latency to reach maximum tumescence (t(20) 
= .12, p = .90, d = .03); and erectile onset (t(20) = 1.60, p = .13, d = .35)). 
5.3.2   Analyses of continuous self-reported sexual arousal 
Data from two participants were not interpretable because of software 
malfunction, and therefore analyses of subjective sexual arousal were conducted on the 
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remaining subsample with valid assessments (n = 19). Contrary to my hypotheses, one-
way repeated measures ANOVAs revealed no significant across-session differences for 
within-session percent change (F(2,36) = .01, p = .99, η2 < .01) (see Figure 9), latency to 
reach maximum arousal (F(2,36) = .28, p = .76, η2 = .02) (see Figure 10), or rate of onset 
to maximum arousal (F(2,36) = 1.67, p = .21, η2 = .09) (see Figure 11). This indicated 






































Figure 11. Percent Increase in Continuous Self-Reported Sexual Arousal for Successful Quitters as a 
Function of Time.  
Bars represent mean percent increases in subjective sexual arousal (the difference between mean arousal scores 
during the erotic and neutral film stimuli divided by the mean of the neutral stimulus, and then multiplied by 
100). Error bars represent standard errors of the means. Means were not significantly different from one another 












































































Figure 12. Time to Reach Maximum Self-Reported Sexual Arousal for Successful Quitters as a 
Function of Time.  
Bars represent mean latencies to reach maximum subjective sexual arousal responses. Error bars represent 


















Figure 13. Rate of Onset to Reach Maximum Self-Reported Sexual Arousal for Successful Quitters 
as a Function of Time.  
Bars represent mean slope values to reach maximum subjective sexual arousal responses. Error bars represent 
standard errors of the means. Means were not significantly different from one another (p > .05).  
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5.3.3   Analyses of the relationship between physiological and subjective sexual arousal 
responses 
Analyses of men with valid physiological and subjective sexual arousal 
assessments for all sessions (n = 19), revealed that erectile responses and self-reported 
sexual arousal responses were significantly associated with one another at baseline (r(17) 
= .67, p < .01, R2 = .45), but not at mid-treatment (r(17) = .35, p = .15, R2 = .12) or at 
follow-up (r(17) = .21, p = .40, R2 = .04). This was likely due to the fact that men did not 
show a differential change across time with respect to continuous subjective sexual 
arousal responses as they did with physiological genital arousal responses.  
5.3.4   Analyses of self-reported sexual functioning 
Participants demonstrated a significant main effect of time for erectile function 
(F(2,40) = 4.69, p = .02, η2 = .19), intercourse satisfaction (F(2,38) = 6.74, p < .01, η2 = 
.26), and overall sexual functioning (F(2,40) = 6.23, p < .01, η2 = .24). Paired samples 
contrasts indicated that these measures significantly increased from baseline to follow-up 
(erectile function (t(20) = 2.90, p < .01, d = .63) (18 of 21 men); intercourse satisfaction 
(t(20) = 2.01, p = .05, d = .44) (16 of 21 men); overall sexual functioning (t(20) = 3.13, p 
< .01, d = .68) (14 of 21 men)), as well as from mid-treatment to follow-up (erectile 
function (t(20) = 2.05, p < .05, d = .45) (17 of 21 men); intercourse satisfaction (t(20) = 
2.17, p = .04, d = .47) (19 of 21 men); overall sexual functioning (t(20) = 2.44, p = .02, d 
= .53) (16 of 21 men)). These variables did not differ from baseline to mid-treatment.  
The other sexual function domains increased across sessions; however these 



































Figure 14. Changes in Sexual Function for Successful Quitters as a Function of Time.  
Bars represent mean scores of sexual function domains of the IIEF. Error bars represent standard errors of the means. Bars without common superscripts 
are statistically different from one another (p < .05) within each IIEF domain. Bars without any superscripts were not statistically different from one 
another within each domain.   
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.16, η2 = .09): sexual desire (F(2,40) = 1.94, p = .16, η2 = .09); overall satisfaction 
(F(2,40) = 1.42, p = .25, η2 = .07)). Mean IIEF sexual function domain scores for each 
session are presented in Figure 12.  
With respect to changes in ED status as a function of smoking cessation, 24% (5 
of 21) met criteria for ED at baseline, and 19% (4 of 21) and 5% (1 of 21) met criteria for 
ED at mid-treatment and follow-up, respectively. This corresponded to a statistically 
significant decrease in ED from both baseline to follow-up (χ2(1) = 4.20, p < .05; φ = 
.45) and from mid-treatment to follow-up (χ2(1) = 4.46, p < .05; φ = .46). There were no 
statistically significant changes from baseline to mid-treatment (χ2(1) = .26, p = .68; φ = 
.11).  
5.3.5   Analyses of cardiovascular measures 
Although participants showed improvements in cardiovascular measures, one-way 
repeated measures ANOVAs revealed no statistically significant across-session 
differences in systolic (F(2,42) = 2.20, p = .13, η2 = .10) or diastolic (F(2,42) = .88, p = 
.42, η2 = .04) blood pressures. With respect to analyses of heart rate, there was an overall 
main effect of time (F(2,36) = 3.77, p = .05, η2 = .17), but no main effect of session 
(F(2,36) = 2.12, p = .14, η2 = .11), and no significant time × session interaction (F(4,36) 
= .41, p = .72, η2 = .02). This indicated that irrespective of smoking cessation, heart rates 
demonstrated significant within-session changes. More detailed analyses revealed higher 
heart rates during the erotic film compared to during the neutral film (p = .001, d = .93). 
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Heart rates assessed before film onset did not differ significantly from mean heart rates 
during the neutral film (p = .10, d = .41) or erotic film (p = .67, d = .09) presentations.     
Participants showed differences in BMI across the three experimental sessions 
(F(2,42) = 13.28, p < .001, η2 = .39). Specifically, men demonstrated significantly higher 
BMI at follow-up compared to both mid-treatment (t(21) = 4.12, p < .001, d = .88) and 
baseline (t(21) = 4.02, p = .001, d = .86), but did not show differences between baseline 
and mid-treatment (t(21) = 1.93, p = .07, d = .41). This indicated that men gained weight 
as a result of nicotine discontinuation (see Figure 13), which is a well-established 





















Figure 15. Changes in Body Mass Index for Successful Quitters as a Function of Time.  
Bars represent mean values. Error bars represent standard errors of the means. Bars without common 
superscripts are statistically different from one another (p < .05). 
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5.3.6   Analyses using the last observation carried forward technique 
Results of physiological sexual arousal analyses (n = 47) were similar to those 
using list-wise deletion (see Table 5 for overall summary of results; see Table 6 for 
across-session comparisons in terms of effect sizes for physiological sexual arousal by 
missing data approach). Specifically, there was a significant main effect of time for the 
six physiological sexual arousal variables (erectile tumescence raw change (F(2,90) = 
4.85, p = .02, η2 = .10); erectile tumescence percent change (F(2,90) = 4.63, p = .01, η2 = 
.10); raw change in maximum erectile response (F(2,90) = 7.84, p = .001, η2 = .15); 
percent change in maximum erectile response (F(2,90) = 3.21, p = .05, η2 = .08); latency 
to reach maximum arousal (F(2,90) = 4.77, p = .02, η2 = .09); rate of onset to maximum 
erection (F(2,90) = 6.76, p < .01, η2 = .13).  
Paired comparisons indicated greater within-session changes for all six 
physiological indices at mid-treatment compared to baseline: greater erectile tumescence 
raw values (p = .03, d = .32) (38 of 47 men), greater percent changes in erectile 
tumescence (p = .04, d = .30) (38 of 47 men), greater maximum tumescence (p < .01, d = 
.42) (40 of 47 men), greater percent increases in maximum tumescence (p = .02, d = .34) 
(40 of 47 men), lower latency to reach maximum tumescence (p = .03, d = .34) (39 of 47 
men), and faster erectile onset (p = .01, d = .38) (44 of 47 men). This corresponded to a 
21%, 22%, 3%, 20%, and 37% increase in erectile response, percent change in erectile 
tumescence, raw change in maximum tumescence, percent change in maximum 
tumescence, and rate of onset, respectively. Participants showed a 16% reduction in 
latency to reach maximum erection.   
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These indices were also improved at follow-up compared to baseline (raw change 
in erectile tumescence (p = .02, d = .36) (39 of 47 men); percent change in erectile 
tumescence (p = .02, d = .35) (39 of 47 men); maximum tumescence (p < .01, d = .47) 
(39 of 47 men); percent change in maximum tumescence (p < .01, d = .46) (39 of 47 
men); latency to maximum tumescence (p = .02, d = .34) (38 of 47 men); erectile onset (p 
< .01, d = .41) (43 of 47 men)). Participants showed a 26%, 27%, 4%, 30%, and 56% 
increase in erectile response, percent increase in erectile tumescence, maximum 
tumescence, percent change in maximum tumescence, and rate of onset, respectively. 
Participants showed a 17% reduction in time to reach maximum erection.  
There were no differences between mid-treatment and follow-up with respect to 
raw change in erectile tumescence (p = .45, d = .11), percent change in erectile 
tumescence (p = .45, d = .11), raw change in maximum tumescence (p = .25, d = .17), 
percent change in maximum tumescence (p = .09, d = .25), and latency to maximum 
tumescence (p = .80, d = .04)). Erectile onset was significantly improved at follow-up 
compared to mid-treatment (p = .05, d = .29).  
Similar to list-wise deletion, there were no across-session differences in self-
reported sexual arousal variables (percent change in sexual arousal (F(2,90) = .03, p = 
.97, η2 < .01); latency to reach maximum arousal (F(2,90) = .21, p = .81, η2 = .01); rate of 
onset to maximum arousal (F(2,90) = 1.02, p = .35, η2 = .02) (see Table 5 and Table 7).  
 Participants again demonstrated differences in erectile function (F(2,90) = 7.61, p 




















Physiological sexual arousal variables
      Magnitude of change in penile 
           tumescence (mm)
MT > B** FU > B* ns MT > B*   FU > B* ns MT > B** FU > B** ns
      Percent change in penile tumescence ns FU > B* ns MT > B*   FU > B* ns MT > B*   FU > B** ns
      Maximum arousal (mm) MT > B** FU > B* ns MT > B** FU > B** ns MT > B*** FU > B*** ns
      Percent change in maximum arousal ns FU > B*** ns MT > B* FU > B** ns MT > B** FU > B*** FU > MT*
      Latency to reach maximum arousal (sec) MT < B*   FU < B* ns MT < B*   FU < B* ns MT < B*   MT < B** ns
      Rate of onset to maximum erection
          (slope)
MT > B** FU > B* ns MT > B** FU > B** FU > MT* MT > B*   FU > B*** FU > MT***
Self-reported sexual arousal variables
      Percent change in arousal ns ns ns ns ns ns ns ns ns
      Latency to reach maximum arousal (sec) ns ns ns ns ns ns ns ns ns
      Rate of onset to maximum arousal
           (slope)
ns ns ns ns ns ns ns ns ns
Self-reported sexual functioning*
      Mean erectile function score ns FU > B** FU > MT* ns FU > B*** FU > MT* ns FU > B*** FU > MT**
      Mean orgasmic function score ns ns ns ns ns ns ns FU > B* ns
      Mean sexual desire score ns ns ns ns FU > B* ns ns ns ns
      Mean intercourse satisfaction score ns FU > B* FU > MT* ns FU > B* FU > MT** ns ns ns
      Mean overall satisfaction score ns ns ns ns ns ns ns ns ns
      Mean overall sexual functioning
           (total score)
ns FU > B** FU > MT* ns FU > B** FU > MT** ns FU > B*** FU > MT**
      Proportion meeting criteria for ED† ns FU < B* FU < MT* ns FU < B** FU < MT** ns FU < B** FU < MT**
List-wise deletion (n = 19-21) Last observation carried forward (n = 47) Multiple imputation  (n = 42)
 
Table 5. Overall Results of Across-Session Comparisons within each Primary Outcome Variable by Missing Data Approach for Successful Quitters.  
Abbreviations: B = baseline; ED = erectile dysfunction; FU = follow-up; MT = mid-treatment; ns = not statistically significant. 
Note: *p < .05, **p < .01, ***p < .001 
*As per the International Index of Erectile Function (IIEF).
 78
sexual functioning (F(2,90) = 7.73, p = .001, η2 = .15) (see Table 5 and Table 8). 
Specifically, paired samples contrasts indicated significant increases from 
baseline to follow-up for erectile function (p = .001, d = .50) (43 of 47 men), intercourse 
satisfaction (p = .04, d = .31) (37 of 47 men), and overall sexual functioning (p < .01, d = 
.49) (37 of 47 men). Additionally, men showed increases from mid-treatment to follow-
up for erectile function (p = .02, d = .36) (43 of 47 men), intercourse satisfaction (p < .01, 
d = .40) (45 of 47 men), and overall sexual functioning (p < .01, d = .41) (42 of 47 men). 
There were no statistically significant differences from baseline to mid-treatment (all ps > 
.05). Different from the list-wise technique, sexual desire became a significant sexual 
function domain using LOCF (F(2,90) = 3.83, p = .03, η2 = .08), with men showing 
significantly higher sexual desire at follow-up compared to baseline (p = .02, d = .35), but 
not from baseline to mid-treatment (p = .21, d = .19), or from mid-treatment to follow-up 
(p = .16, d = .21). Orgasmic function (F(2,90) = 2.66, p = .10, η2 = .06) and overall sexual 
satisfaction (F(2,90) = .80, p = .44, η2 = .02) scores did not show statistically significant 
across-session differences.  
With respect to changes in ED status as a function of smoking cessation, 28% (13 
of 47) met criteria for ED at baseline, and 21% (10 of 47) and 11% (5 of 47) met criteria 
for ED at mid-treatment and follow-up, respectively. This corresponded to a statistically 
significant decrease in ED from both baseline to follow-up (χ2(1) = 6.81, p = .01; φ = 
.38) and from mid-treatment to follow-up (χ2(1) = 7.76, p = .01; φ = .41). There were no 
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statistically significant changes from baseline to mid-treatment (χ2(1) = .75, p = .43; φ = 
.13) (see Table 5 and Table 8).  
5.3.7  Analyses using multiple imputation 
  Of the 2925 possible data points†, 863 (29.5%) were missing and estimated with 
FIML procedures. The patterns of missing data in the current study were consistent with 
the assumption that the data are missing at random, as determined by Little’s (1988) 
Missing Completely at Random Test (χ2(304) = 72.84, p = .99). Full information 
maximum likelihood was thus an appropriate estimator for the missing data. 
Results of physiological sexual arousal analyses for men who were abstinent at 
follow-up (n = 42) were similar to analyses using both list-wise deletion and LOCF (see 
Tables 4 – 5). There was a significant main effect of time for raw changes in erectile 
tumescence (F(2,80) = 3.98, p = .02, η2 = .09), maximum erectile response (F(2,80) = 
11.40, p < .001, η2 = .22), percent change in maximum erectile response (F(2,80) = 4.14, 
p = .02, η2 = .09); time to reach maximum arousal (F(2,80) = 4.39, p = .02, η2 = .10), and 
rate of onset to reach maximum erection (F(2,80) = 4.69, p = .02, η2 = .11). There were 
no across-session differences in percent changes in erectile tumescence (F(2,80) = 1.59, p 
= .21, η2 = .04). 
Planned comparisons revealed that participants exhibited greater within-session 
erectile response (p = .01, d = .40) (29 of 42 men), greater maximum tumescence (p = 
.001, d = .57) (32 of 42 men), greater within-session percent increase in maximum 
                                                 
† (65 participants × 14 outcome variables × 3 assessments) + (65 participants × 3 smoking characteristic 
variables (end-point smoking status, total cigarette consumption throughout the study, total days of patch 
use). 
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tumescence (p < .01, d = .45) (32 of 42 men), smaller latency to reach maximum 
tumescence (p = .05, d = .29) (28 of 42 men), and faster erectile onset (p = .02, d = .46) 
(37 of 42 men) at mid-treatment compared to baseline. This corresponded to a 37%, 5%, 
26%, and 49% increase in erectile response, maximum tumescence, percent increase in 
maximum tumescence, and rate of onset, respectively, and a 15% reduction in time to 
reach maximum erection.  
These indices were also improved at follow-up compared to baseline (erectile 
tumescence (p = .01, d = .39) (30 of 42 men); maximum tumescence (p = .001, d = .58) 
(31 of 42 men); percent change in maximum tumescence (p < .001, d = .75) (31 of 42 
men); latency to reach maximum tumescence (p < .01, d = .45) (30 of 42 men); and 
erectile onset (p < .001, d = .62) (38 of 42 men)). Participants showed a 32%, 5%, 41%, 
and 108% increase in erectile response, maximum tumescence, percent change in 
maximum erectile response, and rate of onset, respectively. Participants showed a 21% 
reduction in time to reach maximum erection.  
There were no differences between mid-treatment and follow-up with respect to 
raw change in erectile tumescence, percent change in penile tumescence, maximum 
arousal, and latency to maximum arousal (all ps > .05). Both erectile onset (p = .001, d = 
.67) and percent change in maximum arousal (p = .02, d = .40) were significantly greater 
at follow-up compared to mid-treatment. 
Similar to both list-wise deletion and LOCF, there were no across-session 
differences in percent change in self-reported sexual arousal (F(2,80) = .42, p = .64, η2 = 
.01), latency to reach subjective maximum arousal (F(2,80) = .25, p = .78, η2 = .01), or 
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Change 95% CI d p Change 95% CI d p Chang
e
95% CI d p
List-wise deletion (n = 21)
      Magnitude of change in penile 
           tumescence (mm) 2.86 .68, 5.04 .60 .01 2.93 .38, 5.48 .52 .03 .07 2.07 - 2.22 .02 .94
      Percent change in penile tumescence 1.86 -1.01, 4.72 .29 .19 3.24 .89, 5.58 .45 .03 .07 -2.10, 2.24 .01 .95
      Maximum arousal (mm) 5.13 1.60, 8.67 .66 .01 5.38 1.17, 9.59 .58 .02 .25 2.76 - 3.26 .04 .87
      Percent change in maximum arousal 2.89 -.44, 6.23 .38 .09 6.29 2.89, 9.69 .74 .001 1.53 -1.44, 4.50 .23 .30
      Latency to reach maximum arousal (sec) -81.7 -146.16, -17.26 .58 .02 -84.2 -152.33, -16.03 .56 .02 -2.47 -43.95, -39.01 .03 .90
      Rate of onset to maximum arousal* 5.67 1.70, 9.64 .65 .01 9.24 2.04, 16.45 .58 .02 3.57 1.08, 8.23 .35 .13
Last observation carried forward (n = 47)
      Magnitude of change in penile 
           tumescence† (mm)
1.84 .17, 3.51 .32 .03 2.24 .43, 4.05 .36 .02 .40 -.66, 1.45 .11 .45
      Percent change in penile tumescence 1.83 .06, 3.60 .30 .04 2.24 .35, 4.13 .35 .02 .41 -.66, 1.49 .11 .45
      Maximum arousal† (mm) 3.67 1.08, 6.27 .42 <.01 4.78 1.77, 7.79 .47 <.01 1.11 -.80, 3.01 .17 .25
      Percent change in maximum arousal 2.94 .43, 5.46 .34 .02 4.44 1.63, 7.25 .46 <.01 1.49 -.23, 3.22 .25 .09
      Latency to reach maximum arousal† (sec) -37.9 -70.87, -4.87 .34 .03 -40.1 -74.47, -5.69 .34 .02 -2.21 -19.95, 15.54 .04 .80
      Rate of onset to maximum arousal*† 2.71 .62, 4.80 .38 .01 4.97 1.41, 8.54 .41 <.01 2.26 -.02, 4.54 .29 .05
Multiple imputation  (n = 42)
      Magnitude of change in penile 
           tumescence† (mm)
2.61 .58, 4.64 .40 .01 2.17 .46, 3.88 .39 .01 -.44 -2.01, 1.13 .02 .57
      Percent change in penile tumescence 2.16 .41, 3.91 .39 .02 2.73 1.10, 4.37 .52 <.01 .57 -.65, 1.79 .15 .35
      Maximum arousal† (mm) 6.12 2.78, 9.45 .57 .001 5.13 2.34, 7.92 .58 .001 .98 -3.05, 1.08 .15 .34
      Percent change in maximum arousal 3.53 1.11, 5.95 .45 <.01 5.59 3.26, 7.92 .75 <.001 2.06 .37, 3.74 .40 .02
      Latency to reach maximum arousal† (sec) -40.4 -85.08, 4.23 .29 .05 -70.0 -108.56, 19.43 .45 <.01 -23.6 -52.90, 5.76 .25 .11
      Rate of onset to maximum arousal*† 3.52 .62, 6.43 .46 .02 8.68 4.41, 12.95 .62 <.001 5.16 2.16, 8.15 .67 .001
Baseline to mid-treatment Baseline to follow-up Mid-treatment to follow-up
Table 6. Across-Session Comparisons in Terms of Effect Sizes for each Physiological Sexual Arousal Measure by Missing Data Approach for 
Successful Quitters.  
Abbreviations: CI = confidence interval; d = Cohen’s d; p = two-tailed alpha value. 
*Multiplied by 103. 
†Based on adjusted cell means after controlling for age, pack years, and total cigarettes smoked throughout the study.  
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Change 95% CI d p Change 95% CI d p Change 95% CI d p
List-wise deletion (n = 19)*
      Percent change in arousal -.59 -8.13, 6.94 .04 .87 -.43 -8.22, 7.36 .03 .91 .16 -10.21, 10.54 .01 .97
      Latency to reach maximum arousal (sec) 4.05 -56.05, 64.16 .03 .89 -18.74 -85.60, 48.12 .14 .56 -22.79 -99.50, 53.91 .14 .54
      Rate of onset to maximum arousal† 3.84 -.61, 8.29 .42 .09 8.53 -2.90, 19.95 .36 .13 4.68 -7.11, 16.49 .19 .42
Last observation carried forward (n = 46)‡
      Percent change in arousal¥ -.01 -3.24, 3.23 <.01 .99 .38 -3.09, 3.86 .03 .82 .39 -3.77, 4.55 .03 .85
      Latency to reach maximum arousal¥ (sec) 6.73 -24.15, 37.62 .07 .66 -3.78 -38.85, 31.30 .03 .83 -10.51 -43.21, 22.19 .10 .52
      Rate of onset to maximum arousal†¥ 1.56 -1.40, 4.51 .16 .29 3.20 -2.15, 8.56 .18 .24 1.64 -3.22, 6.50 .10 .50
Multiple imputation  (n = 42)
      Percent change in arousal¥ -2.76 -7.30, 1.78 .19 .23 .69 -3.34, 4.72 .05 .73 3.45 -2.36, 9.25 .19 .24
      Latency to reach maximum arousal¥ (sec) 13.23 -30.92, 57.37 .09 .55 -22.06 -68.90, 24.78 .15 .35 -35.28 -82.45, 11.89 .23 .14
      Rate of onset to maximum arousal†¥ -.97 -6.09, 4.15 .05 .70 7.22 .79, 15.66 .32 .08 6.19 .02, 13.65 .29 .07
Baseline to mid-treatment Baseline to follow-up Mid-treatment to follow-up
Table 7. Across-Session Comparisons in Terms of Effect Sizes for each Subjective Sexual Arousal Measure by Missing Data Approach for 
Successful Quitters.  
Abbreviations: CI = confidence interval; d = Cohen’s d; p = two-tailed alpha value. 
*Data missing for 2 participants. 
†Multiplied by 104. 
‡Data missing for 1 participant. 
¥Based on adjusted cell means after controlling for age, pack years, and total cigarettes smoked throughout the study.  
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Table 8. Across-Session Comparisons in Terms of Effect Sizes for each Self-Reported Sexual Function Measure by Missing Data Approach for 
Successful Quitters.  
Abbreviations: CI = confidence interval; ED = erectile dysfunction; ES = effect size. 
*Effect sizes in Cohen’s d for all variables, with the exception of number meeting criteria for ED, which is reported  as Cramer’s Phi. 
†As per the IIEF erectile functioning cutoff score of 25. 
‡Based on adjusted cell means after controlling for age, pack years, and total cigarettes smoked throughout the study.  
Change 95% CI ES* p Change 95% CI ES* p Change 95% CI ES* p
List-wise deletion (n = 21)
      Mean erectile function score .29 -.42, .99 .18 .41 1.10 .31, 1.88 .63 <.01 .81 -.01, 1.63 .45 .05
      Mean orgasmic function score .19 -.26, .64 .19 .38 .48 -.06, 1.01 .41 .08 .29 -.24, .81 .25 .27
      Mean sexual desire score .43 -.18, 1.03 .32 .15 .57 -.14, 1.29 .36 .11 .14 -.42, .71 .12 .60
      Mean intercourse satisfaction score .10 -.62, .81 .06 .79 .86 -.03, 1.75 .44 .05 .76 .03, 1.50 .47 .04
      Mean overall satisfaction score .14 -.47, .76 .11 .63 .57 -.25, 1.39 .32 .16 .43 -.33, 1.18 .26 .25
      Mean overall sexual functioning 1.14 -.84, 1.20 .26 .24 3.57 1.19, 5.95 .68 <.01 2.43 .35, 4.51 .53 .02
      Number meeting criteria for ED† -1 -6.07, 4.20 .11 .68 -4 -8.54, .67 .45 <.05 -3 -7.48, 1.46 .46 <.05
Last observation carried forward (n = 47)
      Mean erectile function score‡ .28 -.12, .67 .21 .17 .94 .38, 1.49 .50 .001 .63 .12, 1.14 .36 .02
      Mean orgasmic function score‡ .13 -.20, .46 .11 .44 .39 -.01, .80 .29 .06 .26 -.04, .56 .26 .08
      Mean sexual desire score‡ .21 -.12, .55 .19 .21 .48 .07, .88 .35 .02 .22 -.09, .52 .21 .16
      Mean intercourse satisfaction score‡ <.01 -.45, .45 <.01 .99 .57 .03, 1.10 .31 .04 .50 .13, .87 .40 <.01
      Mean overall satisfaction score‡ .04 -.26, .34 .04 .78 .22 -.20, .64 .15 .30 .17 -.19, .54 .14 .34
      Mean overall sexual functioning‡ .67 -.53, 1.85 .16 .27 2.59 1.01, 4.17 .49 <.01 1.78 .51, 3.06 .41 <.01
      Number meeting criteria for ED† -3 -9.77, 5.21 .13 .43 -8 -15.20, .45 .38 .01 -5 -12.00, 2.12 .41 .01
Multiple imputation  (n = 42)
      Mean erectile function score‡ .41 -.06, .88 .27 .09 1.25 .63, 1.87 .63 <.001 .84 .34, 1.34 .52 <.01
      Mean orgasmic function score‡ .22 -.14, .57 .19 .23 .41 .01, .80 .32 .05 .19 -.09, .47 .21 .18
      Mean sexual desire score‡ .39 -.09, .87 .25 .11 .58 .09, 1.08 .37 .02 .19 -.14, .53 .18 .25
      Mean intercourse satisfaction score‡ .05 -.52, .61 .03 .86 .53 -.14, 1.21 .25 .12 .49 -.03, 1.00 .29 .06
      Mean overall satisfaction score‡ .16 -.22, .55 .13 .40 .32 -.25, .90 .18 .26 .16 -.42, .74 .09 .57
      Mean overall sexual functioning‡ 1.44 .12, 2.99 .29 .07 3.16 1.43, 4.88 .57 .001 1.72 .62, 2.82 .49 <.01
      Number meeting criteria for ED† -1 -8.19, 6.25 .06 .72 -7 -13.26, -.82 .41 <.01 -6 -12.16, .01 .41 <.01
Baseline to mid-treatment Baseline to follow-up Mid-treatment to follow-up
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rate of onset to maximum subjective sexual arousal (F(2,80) = 1.81, p = .18, η2 = .04) 
(see Table 5 and Table 7).  
 Results of data analyses for sexual function using FIML for missing data are 
shown in Table 5 and Table 8. With multiple imputation techniques, participants again 
demonstrated differences in erectile function (F(2,80) = 17.20, p < .001, η2 = .30), and 
overall sexual functioning (F(2,80) =5.17, p = .01, η2 = .11), with paired samples 
contrasts indicating significant increases from baseline to follow-up (erectile function (p 
< .001, d = .63) (37 of 42 men); overall sexual functioning (p = .001, d = .57) (30 of 42 
men)), as well as from mid-treatment to follow-up (erectile function (p < .01, d = .52) (37 
of 42 men); overall sexual functioning (p < .01, d = 49) (31 of 42 men)). There were no 
differences from baseline to mid-treatment with respect to these measures. With the 
FIML approach, orgasmic functioning became statistically significant (F(2,80) =6.01, p <  
.01, η2 = .13), with men demonstrating significantly higher orgasmic functioning at 
follow-up compared to baseline (p = .05, d = 32) (33 of 42 men). Sexual desire (F(2,80) 
=2.15, p = .13, η2 = .05), intercourse satisfaction (F(2,80) = .01, p < .99, η2 < .001), and 
overall satisfaction (F(2,80) =.63, p = .52, η2 = .02) scores did not show statistically 
significant across-session differences.  
 With respect to changes in ED status as a function of smoking cessation, 21% (9 
of 42) met criteria for ED at baseline, and 19% (8 of 42) and 5% (2 of 42) met criteria for 
ED at mid-treatment and follow-up, respectively. This corresponded to a statistically 
significant decrease in ED from both baseline to follow-up (χ2(1) = 6.93, p < .01; φ = 
.41) and from mid-treatment to follow-up (χ2(1) = 7.07, p < .01; φ = .41). There were no 
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statistically significant changes from baseline to mid-treatment (χ2(1) = .14, p = .72; φ = 
.06) (see Table 5 and Table 8).    
5.3.8   Post hoc analyses  
Results of the linear regression analyses revealed no association between changes 
in positive affect (PA) and erectile tumescence (r(22) = -2.72, p = .20, adj R2 = .03) or 
between negative affect (NA) and erectile tumescence (r(22) = -.05, p = .82, adj R2 = .04) 
between baseline and follow-up. Similarly, there was no association between changes in 
PA or NA with respect to self-reported sexual arousal (PA: r(22) = .28, p = .19, adj R2 = 
.04; NA: r(22) = .06, p = .77, adj R2 = .04) or self-reported sexual functioning (PA: r(22) 
= .24, p = .26, adj R2 = .01; NA: r(22) = .07, p = .73, adj R2 = .04). Taken together, these 
results indicate that there was no statistically significant relationship between across-
session changes in mood and sexual health indices. Analyses using LOCR and multiple 












  Statistic 
  β Adjusted R2 t p 
List-wise deletion          
     Physiological sexual arousal (n = 24)         
           Positive affect -.27 .03 -1.32 .20 
           Negative affect -.05 .04 -.23 .82 
     Subjective sexual arousal* (n = 23)         
           Positive affect .28 .04 1.36 .19 
           Negative affect .06 .04 .29 .77 
     Self-reported sexual function† (n = 24)         
           Positive affect .24 .01 1.15 .26 
           Negative affect .07 .04 .34 .74 
Last observation carried forward          
     Physiological sexual arousal (n = 46)         
           Positive affect -.02 .02 -.15 .89 
           Negative affect .13 .01 .87 .39 
     Subjective sexual arousal* (n = 45)         
           Positive affect .30 .07 1.76 .07 
           Negative affect .08 .02 .55 .59 
     Self-reported sexual function*† (n = 45)         
           Positive affect .26 .05 1.78 .08 
           Negative affect .07 .02 .48 .64 
Multiple imputation         
     Physiological sexual arousal (n = 42)         
           Positive affect -.18 .01 -1.16 .25 
           Negative affect .03 .02 .18 .86 
     Subjective sexual arousal (n = 42)         
           Positive affect .24 .03 1.56 .13 
           Negative affect .07 .02 .43 .67 
     Self-reported sexual function† (n = 42)         
           Positive affect -.01 <.01 -.07 .94 
           Negative affect .17 <.01 1.06 .30 
  
Table 9. Results of Association between Affect and each Primary Outcome Measure by Missing 
Data Approach for Successful Quitters.  
 *Data was missing for 1 participant.  
 †Measured with the International Index of Erectile Function.  
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5.4   Results of major study hypotheses for all participants (using intent-to-treat  
        analyses) 
5.4.1   Analyses of physiological sexual arousal 
 The results for the physiological sexual arousal outcome variables are 
summarized in Table 10, using 2 (group: successful quitter, relapser) × 3 (time: baseline, 
mid-treatment, follow-up) repeated measures ANCOVA. There was a significant 
group×time interaction effect for all six outcome measures: raw change in erectile 
tumescence (F(4,124) = 4.44, p < .01, η2 = .13) (see Figure 16), percent change in penile 
tumescence (F(4,124) = 8.93, p < .001, η2 = .22) (see Figure 17), raw change in 
maximum erectile response (F(4,124) = 4.47, p < .01, η2 = .13) (see Figure 18), percent 
change in maximum erectile response (F(4,124) = 5.17, p = .001, η2 = .14) (see Figure 
19), latency to reach maximum arousal (F(4,124) = 5.08, p = .001, η2 = .14) (see Figure 
20), and rate of onset to maximum erection (F(4,124) = 4.74, p = .001, η2 = .13) (see 
Figure 21).  
Post-hoc tests of between-subjects contrasts revealed significantly greater percent 
increases in erectile tumescence at follow-up among successful quitters compared to 
those that relapsed (p = .02, d = .31). Successful quitters, compared to relapsers, also 
demonstrated a statistical trend toward greater within-session changes in penile 
tumescence (p = .08, d = .22) and greater within-session percent change in maximum 
erection (p = .09, d = .21) at the follow-up evaluation. There were no between-group 
differences at baseline or mid-treatment for these outcome measures (all ps > .05).  
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Figure 16. Raw Changes in Erectile Tumescence for all Participants as a Function of Time.  
Bars represent mean within-session erectile tumescence change scores (mean tumescence during erotic stimulus 
minus mean tumescence during neutral stimulus). Error bars represent standard errors of the means. Means have 
been adjusted for pack years, total cigarette consumption throughout enrollment, baseline erectile functioning, 














































































Figure 17. Percent Changes in Erectile Tumescence for all Participants as a Function of Time.  
Bars represent mean within-session percent changes in erectile tumescence (mean tumescence during erotic 
stimulus minus mean tumescence during neutral stimulus divided by mean tumescence during neutral stimulus). 
Error bars represent standard errors of the means. Means have been adjusted for pack years, total cigarette 
consumption throughout enrollment, baseline erectile functioning, and smoking status at mid-treatment. 
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Figure 19. Percent Changes in Maximum Erectile Response for all Participants as a Function of Time.  
Bars represent mean within-session percent changes in maximum erectile tumescence scores (maximum tumescence 
during erotic stimulus minus mean tumescence during neutral stimulus divided by mean tumescence during neutral 
stimulus). Error bars represent standard errors of the means. Means have been adjusted for pack years, total cigarette 
























































































    
 
Figure 18. Raw Changes in Maximum Erectile Response for all Participants as a Function of Time.  
Bars represent mean maximum erectile tumescence scores. Error bars represent standard errors of the means. Means 
have been adjusted for pack years, total cigarette consumption throughout enrollment, baseline erectile functioning, 
and smoking status at mid-treatment.  
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Figure 21. Rate of Onset to Reach Maximum Erection for all Participants as a Function of Time.  
Bars represent mean slope values to reach maximum erectile response. Error bars represent standard errors of the 
means. Means have been adjusted for pack years, total cigarette consumption throughout enrollment, baseline 




























































































   










Figure 20. Latency to Reach Maximum Erection for all Participants as a Function of Time.  
Bars represent mean latencies to reach maximum erectile response. Error bars represent standard errors of the 
means. Means have been adjusted for pack years, total cigarette consumption throughout enrollment, baseline 
erectile functioning, and smoking status at mid-treatment. 
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Mean* (SE)* [95%  CI]* Mean* (SE)* [95%  CI]* P value†
Raw change in penile tumescence 
      Baseline .39 (.45) [-.52, 1.29] .83 (.08) [.67, 1.00]
      Mid-treatment 1.21 (.41) [.39, 2.02] .99 (.08) [.84, 1.14] <.01
      4-week follow-up 1.79 (.39) [1.00, 2.57] 1.08 (.07) [.94, 1.23]
Percent change in penile 
      Baseline -1.70 (10.62) [-22.92, 19.53] 7.56 (.69) [6.17, 8.94]
      Mid-treatment 17.80 (11.01) [-4.22, 39.81] 9.11 (.72) [7.68, 10.55] <.001
      4-week follow-up 34.20 (9.95) [14.31, 54.09] 9.29 (.65) [7.99, 10.58]
Maximum penile tumescence (cm)
      Baseline 10.02 (3.67) [2.68, 17.37] 11.73 (.18) [11.36, 12.09]
      Mid-treatment 11.85 (3.25) [5.36, 18.35] 12.14 (.16) [11.82, 12.45] <.01
      4-week follow-up 14.65 (3.30) [8.05, 21.25] 12.26 (.16) [11.94, 12.59]
Percent change in maximum 
tumescence (cm)
      Baseline 11.01 (18.01) [-24.98, 46.99] 13.69 (.89) [11.92, 15.46]
      Mid-treatment 33.83 (20.55) [-7.24, 74.90] 15.78 (1.01) [13.76, 17.80] .001
      4-week follow-up 59.81 (24.58) [10.67, 108.94] 18.43 (1.21) [16.01, 20.85]
Latency to reach maximum arousal 
(sec)
      Baseline 371 (84.1) [202.8, 539.1] 211 (15.4) [180.8, 242.3]
      Mid-treatment 119 (64.9) [-11.1, 248.5] 190 (11.9) [166.2, 213.7] .001
      4-week follow-up 125 (75.9) [-26.8, 276.5] 201 (13.9) [173.7, 229.1]
Rate of onsent to maximum arousal 
(slope)‡
      Baseline 4.5 (6.41) [-8.26, 17.37] 9.7 (1.17) [7.38, 12.06]
      Mid-treatment 11.8 (5.64) [.54, 23.12] 10.9 (1.03) [8.81, 12.93] .001
      4-week follow-up 24.3 (8.32) [7.61, 40.89] 16.4 (1.52) [13.38, 19.46]
Outcome measure
Successful 
quitters (n = 20)
Unsuccessful 






Table 10. Summary of Results for Intent-to-Treat Analyses of Physiological Sexual Arousal.  
Abbreviations: CI = confidence interval; SE = standard error. 
*Adjusted for pack years, total cigarette consumption throughout enrollment, baseline erectile functioning, baseline 
drinking severity, and smoking status at mid-treatment assessment. 
†P value based on Greenhouse-Geisser adjustment for the interaction between group and time from analysis of 
variance (ANOVA) model covarying for pack years, total cigarette consumption throughout enrollment, baseline 
erectile functioning, baseline drinking severity, and smoking status at mid-treatment assessment. 
‡Original values multiplied by 103. 
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Additionally, there was a statistically significant improvement in successful 
quitters versus relapsers at both mid-treatment (p < .01, d = .66) and 4-week follow-up (p 
< .01, d = .67), compared with baseline, for latency to maximum arousal. There were no 
between-group differences in maximum tumescence; both groups displayed significant 
within-group improvements at follow-up compared to baseline (successful quitters: p = 
.03; d = .52; relapsers: p = .01, d = .70), however, participants that relapsed also 
demonstrated improvement at mid-treatment compared to baseline (p < .001, d = .62). 
Finally, with respect to erectile onset, both groups displayed significant within-group 
improvements at follow-up compared to baseline (successful quitters: p = .04; d = .50; 
relapsers: p < .001, d = .54); however, participants that relapsed, compared to those that 
quit successfully, also demonstrated improvement at follow-up compared to mid-
treatment (p < .001, d = .80). 
5.4.2   Analyses of continuous self-reported sexual arousal 
Results for the subjective sexual arousal outcome variables are summarized in 
Table 11, using 2 (group: successful quitter, relapser) × 3 (time: baseline, mid-treatment, 
follow-up) repeated measures ANCOVA. Contrary to my hypotheses, there were no 
significant group×time interaction effects for within-session percent change (F(4,124) = 
1.47, p = .22, η2 = .05) (see Figure 22) or for latency to reach maximum arousal 
(F(4,124) = 1.70, p = .15, η2 = .05) (see Figure 23).  
There was, however, a statistically significant group×time interaction for rate of 
onset to maximum arousal (F(4,124) = 4.64, p < .01, η2 = .13) (see Figure 24). Post-hoc 
tests of between-subjects contrasts revealed significantly greater rate of erectile onset at 
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follow-up among successful quitters compared to those that relapsed (p < .001, d = .50). 











































Figure 22. Percent Increase in Continuous Self-Reported Sexual Arousal for all Participants as a 
Function of Time.  
Bars represent mean percent increases in subjective sexual arousal (the difference between mean arousal scores 
during the erotic and neutral film stimuli divided by the mean of the neutral stimulus, and then multiplied by 
100). Error bars represent standard errors of the means. Means have been adjusted for pack years, total cigarette 
consumption throughout enrollment, baseline erectile functioning, and smoking status at mid-treatment. 































































































Figure 23. Latency to Reach Maximum Self-Reported Sexual Arousal for all Participants as a 
Function of Time.  
Bars represent mean latencies to reach maximum subjective sexual arousal responses. Error bars represent 
standard errors of the means. Means have been adjusted for pack years, total cigarette consumption throughout 
enrollment, baseline erectile functioning, and smoking status at mid-treatment. Means were not significantly 
different from one another (p > .05).  
Figure 24. Rate of Onset to Reach Maximum Self-Reported Sexual Arousal for all Participants as a 
Function of Time.  
Bars represent mean slope values to reach maximum subjective sexual arousal responses. Error bars represent 
standard errors of the means. Means have been adjusted for pack years, total cigarette consumption throughout 
enrollment, baseline erectile functioning, and smoking status at mid-treatment. 
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Mean* (SE)* [95% CI]* Mean* (SE)* [95% CI]* P value†
Percent change in subjective 
sexual arousal
      Baseline 68.1 (11.01) [45.99, 90.03] 52.9 (2.68) [47.56, 58.29]
      Mid-treatment 68.7 (11.24) [46.21, 91.14] 51.5 (2.74) [45.99, 56.94] .22
      4-week follow-up 57.8 (11.46) [34.86, 80.71] 48.6 (2.79) [43.05, 54.21]
Latency to  maximum subjective 
sexual arousal (sec)
      Baseline 222 (60.6) [100.5, 342.8] 250 (14.8) [221.2, 280.3]
      Mid-treatment 238 (50.4) [137.2, 338.7] 283 (12.3) [258.1, 307.2] .15
      4-week follow-up 262 (50.4) [161.3, 362.6] 293 (12.3) [268.4, 317.4]
Rate of onsent to maximum 
subjective sexual arousal (slope)‡
      Baseline 11.8 (9.04) [-6.32, 29.85] 13.2 (1.74) [9.68, 16.65]
      Mid-treatment 15.6 (6.73) [2.14, 29.04] 11.7 (1.29) [9.15, 14.33] <.01
      4-week follow-up 49.6 (7.69) [34.26, 65.00] 10.0 (1.48) [7.08, 13.02]
Outcome measure
Successful 
quitters (n = 20)
Unsuccessful 
quitters (n = 45)
 
 
Table 11. Summary of Results for Intent-to-Treat Analyses of Subjective Sexual Arousal.  
Abbreviations: CI = confidence interval; SE = standard error. 
*Adjusted for pack years, total cigarette consumption throughout enrollment, baseline erectile functioning, baseline drinking 
severity, and smoking status at mid-treatment assessment. 
†P value based on Greenhouse-Geisser adjustment for the interaction between group and time from analysis of variance 
(ANOVA) model covarying for pack years, total cigarette consumption throughout enrollment, baseline erectile functioning, 
baseline drinking severity, and smoking status at mid-treatment assessment. 
‡Original values multiplied by 104. 
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5.4.3   Analyses of the relationship between physiological and subjective sexual arousal 
responses 
Analyses of the entire sample revealed that physiological erectile responses and 
self-reported sexual arousal responses were significantly associated with one another at 
baseline (r(63) = .33, p < .01, adj R2 = .10) and mid-treatment (r(63) = .43, p < .001, adj 
R2 = .17), but not at follow-up (r(63) = .23, p = .07, adj R2 = .04). With respect to the two 
treatment groups, successful quitters demonstrated a significant association between 
physiological and self-reported genital responses at the baseline evaluation (r(18) = .58, p 
< .01, adj R2 = .30), but not at the mid-treatment assessment (r(18) = .30, p = .20, adj R2 = 
.04). Unsuccessful quitters displayed significant concordance between these two 
measures at both baseline (r(43) = .31, p = .04, adj R2 = .08) and mid-treatment (r(43) = 
.48, p < .001, adj R2 = .21). Neither of the two groups showed a significant relationship 
between physiological and subjective sexual arousal at follow-up (successful quitters: 
r(18) = .17, p = .48, adj R2 = .03; unsuccessful quitters: r(43) = .26, p = .08, adj R2 = .05).    
Lack of genital-subjective concordance was likely due to the fact that men did not show a 
robust pattern of differential change across time with respect to continuous subjective 
sexual arousal responses as they did with physiological genital arousal responses.  
5.4.4   Analyses of self-reported sexual functioning 
Results of the self-reported sexual function outcome variables are summarized in 
Table 12, using 2 (group: successful quitter, relapser) × 3 (time: baseline, mid-treatment, 
follow-up) repeated measures ANCOVA. Contrary to my hypotheses, there were no 
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statistically significant group×time interaction effects for any of the indices: erectile 
function (F(4,124) = .51, p = .66, η2 = .02); orgasmic function (F(4,124) = 1.28, p = .29, 
η2 = .04), sexual desire (F(4,124) = 1.01, p = .36, η2 = .03), intercourse satisfaction 
(F(4,124) = .55, p = .65, η2 = .02), overall satisfaction (F(4,124) = .51, p = .73, η2 = .02), 
overall sexual function (F(4,124) = .59, p = .67, η2 = .02). This indicated that quitting 
smoking had no effect on self-reported sexual functioning. 
With respect to changes in ED status as a function of smoking cessation, 20% (4 
of 20) of successful quitters met criteria for ED at baseline, and 20% (4 of 20) and 5% (1 
of 19) met criteria for ED at mid-treatment and follow-up, respectively. Among, 
unsuccessful quitters, 33% (15 of 45) met criteria for ED at baseline, and 22% (10 of 45) 
and 13% (6 of 45) met criteria for ED at mid-treatment and follow-up, respectively (see 
Figure 25). This corresponded to a remission rate of 75% for successful quitters and 61% 
for unsuccessful quitters. There were no between-group differences in the rates of ED at 
any time point (baseline: χ2(1) = 1.19, p = .28; φ = .14; mid-treatment: χ2(1) = .04, p = 
.84; φ = .03; follow-up: χ2(1) = .62, p = .43; φ = .10. Similarly multivariate logistic 
regression analyses did not reveal any statistically significant association between 
quitting smoking and erectile dysfunction status at either mid-treatment (adjusted odds 
ratio (AOR) = 1.90; p = .61; CI = .16, 22.57) or 4-week follow-up (AOR = 145.5; p = 
.11; CI = .30, 70,179.45). 
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Mean* (SE)* [95% CI]* Mean* (SE)* [95% CI]* P value†
Erectile function
      Baseline 29.0 (4.53) [19.91, 38.04] 26.9 (.65) [25.69, 28.28]
      Mid-treatment 30.6 (3.32) [23.98, 37.24] 27.7 (.47) [26.77, 28.66] .66
      4-week follow-up 30.4 (2.62) [25.17, 35.65] 28.5 (.38) [27.76, 29.26]
Orgasmic function
      Baseline 10.3 (1.40) [7.47, 13.04] 9.0 (.20) [8.62, 9.42]
      Mid-treatment 10.2 (1.30) [7.56, 12.75] 9.4 (.19) [8.98, 9.72] .29
      4-week follow-up 9.2 (.99) [7.21, 11.18] 9.6 (.14) [9.36, 9.93]
Sexual desire
      Baseline 5.9 (1.50) [2.93, 8.93] 7.4 (.21) [6.98, 7.84]
      Mid-treatment 7.7 (1.58) [4.54, 10.84] 7.3 (.23) [6.80, 7.70] .36
      4-week follow-up 7.7 (1.53) [4.62, 10.75] 7.6 (.22) [7.21, 8.09]
Intercourse satisfaction
      Baseline 11.5 (2.58) [6.37, 16.67] 11.8 (.37) [11.10, 12.57]
      Mid-treatment 11.2 (1.90) [7.43, 15.04] 11.9 (.27) [11.34, 12.43] .65
      4-week follow-up 13.0 (1.93) [11.94, 13.04] 12.4 (.28) [11.94, 13.04]
Overall sexual satisfaction
      Baseline 7.2 (1.18) [4.85, 9.57] 7.8 (.24) [7.28, 8.26]
      Mid-treatment 8.4 (1.17) [6.04, 10.73] 7.5 (.24) [6.99, 7.96] .73
      4-week follow-up 8.0 (1.01) [5.98, 10.02] 8.0 (.21) [7.59, 8.42]
Overall sexual functioning
      Baseline 63.6 (6.25) [51.12, 76.12] 62.9 (1.29) [60.29, 65.43]
      Mid-treatment 66.9 (4.95) [57.09, 76.87] 63.9 (1.02) [61.83, 65.90] .67
      4-week follow-up 67.4 (4.41) [58.56, 76.20] 66.4 (.91) [64.59, 68.22]
Outcome measure
Successful 
quitters (n = 20)
Unsuccessful 
quitters (n = 45)
 
Table 12. Summary of Results for Intent-to-Treat Analyses of Self-Reported Sexual Function.  
Abbreviations: CI = confidence interval; SE = standard error. 
*Adjusted for pack years, total cigarette consumption throughout enrollment, baseline erectile functioning, baseline 
drinking severity, and smoking status at mid-treatment assessment. 
†P value based on Greenhouse-Geisser adjustment for the interaction between group and time from analysis of 
variance (ANOVA) model covarying for pack years, total cigarette consumption throughout enrollment, baseline 









































Figure 25. Proportion of Men Meeting Criteria for Erectile Dysfunction as a Function of Time.  
Bars represent within-group proportions.  
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5.4.5   Analyses of cardiovascular measures 
Results for the cardiovascular measures are summarized in Table 13, using a 
series of 2 (group: successful quitter, relapser) × 3 (time: baseline, mid-treatment, follow-
up) repeated measures ANCOVA, controlling for pack years, BMI, baseline activity 
level, baseline drinking severity, and smoking status at the mid-treatment evaluation. 
Although participants showed improvements in cardiovascular measures, the analyses 
revealed no statistically significant interaction effects for across-session changes in 
systolic (F(4,124) = 2.04, p = .10, η2 = .06) or diastolic (F(4,124) = .20, p = .90, η2 = .01) 
blood pressures. There was also no significant interaction effect resting heart rate 
(F(4,124) = .15, p = .96, η2 = .01). Taken together, these data indicate that those who quit 
smoking did not show relative short-term improvements in cardiovascular measures 
compared to those individuals who relapsed.  
With respect to across-session changes in BMI, there was a moderately 
statistically significant group×time interaction effect (F(4,124) = 2.17, p = .07, η2 = .07) 
(see Figure 26 and Table 13). Post-hoc tests revealed that successful quitters, compared 
to those that relapsed, demonstrated a significant overall main effect of time (F(2,61) = 
6.67, p < .01, η2 = .18. Post hoc tests of within-subjects contrasts indicated that successful 
quitters displayed significantly higher BMI scores at mid-treatment compared to baseline 
(p = .03, d = .83), as well as at follow-up compared to baseline (p = .001, d = .31). There 
was a statistical trend toward higher BMI at follow-up compared to mid-treatment (p = 
.08, d = .39).  
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Taken together, these results in indicated that successful quitters, compared to 
men that relapsed, gained weight as a result of nicotine discontinuation, which is in line 
























Figure 26. Changes in Body Mass Index for all Participants as a Function of Time.  
Bars represent mean values. Error bars represent standard errors of the means. Bars without common 
superscripts are statistically different from one another. There were no statistically significant across-
session changes among those who relapsed. 
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Mean* (SE)* [95% CI]* Mean* (SE)* [95% CI]* P value†
Systolic blood pressure
      Baseline 129.4 (3.01) [19.91, 38.04] 131.5 (2.55) [126.37, 136.56]
      Mid-treatment 125.1 (2.17) [23.98, 37.24] 125.3 (1.84) [121.58, 128.93] .10
      4-week follow-up 128.5 (2.13) [25.17, 35.65] 122.7 (1.80) [119.07, 126.25]
Diastolic blood pressure
      Baseline 86.1 (3.38) [79.27, 92.76] 87.2 (2.90) [81.40, 92.99]
      Mid-treatment 83.4 (1.82) [79.82, 87.08] 83.3 (1.56) [80.16, 86.39] .90
      4-week follow-up 79.6 (1.40) [76.78, 82.37] 79.0 (1.20) [76.78, 82.37]
Heart rate
      Baseline 79.9 (2.31) [75.30, 84.54] 81.2 (1.99) [77.21, 85.15]
      Mid-treatment 77.1 (2.04) [73.00, 81.15] 79.8 (.23) [76.30, 83.30] .96
      4-week follow-up 75.4 (1.76) [71.93, 78.97] 76.4 (.22) [73.42, 79.47]
BMI
      Baseline 26.6 (.81) [25.02, 28.25] 25.8 (.65) [24.46, 27.06]
      Mid-treatment 27.0 (.82) [25.39, 28.66] 26.0 (.66) [24.67, 27.29] .07
      4-week follow-up 27.3 (.81) [25.72, 28.96] 26.1 (.65) [24.79, 27.40]
Outcome measure
Successful 
quitters (n = 20)
Unsuccessful 
quitters (n = 45)
Table 13. Summary of Results for Intent-to-Treat Analyses of Cardiovascular and Anthropometric 
Measures.  
Abbreviations: BMI = body mass index; CI = confidence interval; SE = standard error. 
*Adjusted for pack years, BMI, baseline activity level, baseline drinking severity, and smoking status at the mid-
treatment evaluation. 
†P value based on Greenhouse-Geisser adjustment for the interaction between group and time from analysis of 
variance (ANOVA) model covarying for pack years, BMI, baseline activity level, baseline drinking severity, and 
smoking status at the mid-treatment evaluation. 
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5.4.6   Post hoc analyses  
Results of the linear regression analyses revealed no association between positive 
affect (PA) change scores (follow-up minus baseline) and erectile tumescence change 
scores for either successful (r(18) = -.19, p = .41, adj R2 = .02) or unsuccessful quitters 
(r(43) = -.22, p = .157, adj R2 = .02). Similarly, both successful (r(18) = .10, p = .69, adj 
R2 = .05) and unsuccessful (r(43) = .02, p = .90, adj R2 = .02) quitters displayed no 
association between negative affect (NA) change scores or between erectile tumescence 
change scores.  
There was also no association between changes in PA or NA with respect to self-
reported sexual arousal (PA for successful quitters: r(18) = .17, p = .47, adj R2 = .02; PA 
for unsuccessful quitters: r(43) = -.02, p = .92, adj R2 = .02; NA for successful quitters: 
r(18) = .17, p = .47, adj R2 = .02; NA for unsuccessful quitters: r(43) = -.02, p = .92, adj 
R2 = .02). Finally, there was no association between self-reported sexual functioning 
change scores and between changes in PA or NA (PA for successful quitters: r(18) = .37, 
p = .11, adj R2 = .09; PA for unsuccessful quitters: r(43) = -.03, p = .85, adj R2 = .02; NA 
for successful quitters: r(18) = .09, p = .72, adj R2 = .05; NA for unsuccessful quitters: 
r(43) = .03, p = .84, adj R2 = .02).  
Taken together, these results indicate that there was no statistically significant 
relationship between across-session changes in mood and sexual health indices. Results 
of association between affect and each primary outcome variable for each group 
(successful quitters, relapsers) are summarized in Table 14. 
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β Adj R2 t p β Adj R2 t p
Physiological sexual arousal 
        Positive affect -.19 .02 -.84 .41 -.22 .02 -1.44 .16
        Negative affect .10 .05 .41 .69 .02 .02 .13 .90
Subjective sexual arousal 
        Positive affect .17 .02 .74 .47 -.02 .02 -.10 .92
        Negative affect -.01 .06 -.02 .99 .20 .02 1.31 .20
Self-reported sexual function* 
        Positive affect .37 .09 1.67 .11 -.03 .02 -.20 .85
        Negative affect .09 .05 .37 .72 .03 .02 .20 .84
Successful 
quitters (n = 20)Outcome measure
Unsuccessful 
quitters (n = 45)
Table 14. Results of Intent-to-Treat Analyses of Association between Affect and each Primary 
Outcome Measure.   
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CHAPTER 6: DISCUSSION 
6.1   Overview 
 Cigarette smoking represents the most preventable cause of morbidity and 
mortality in the world today, and is responsible for enormous health-related economic 
burdens. Among other medical sequelae, erectile impairment has been shown to be 
associated with chronic tobacco use. Although quitting smoking substantially enhances 
many aspects of health, the positive health benefits of smoking cessation are not 
sufficient enough for many smokers to consider quitting (e.g., improvements in 
cardiovascular and pulmonary functioning, reduced risk of cancer). Therefore, the 
primary aim of this study was to provide the first empirical investigation of the effects of 
smoking cessation on physiological and subjective indices of sexual health, with the hope 
that the results would serve as a novel and enticing means to influence men to quit 
smoking. 
6.2   Association between smoking cessation and physiological sexual arousal  
 It was hypothesized that men who successfully quit smoking, compared to those 
who relapsed, would display higher physiological sexual arousal responses at the 4-week 
follow-up compared to baseline (while smoking regularly), as a function of eliminating 
chronic nicotine and/or noxious pharmacological agents found within cigarettes. In 
concert with this hypothesis, results indicated that, at follow-up, abstinent men versus 
relapsed participants displayed: (i) significantly improved within-session raw changes in 
erectile tumescence; (ii) improved within-session percent changes in erectile tumescence; 
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and (iii) higher percent changes in maximum tumescence. In these cases, the magnitude 
of across-session changes in genital arousal was moderate (effect sizes ranging from .4 to 
.6); however, differential changes for successful versus unsuccessful quitters was small 
(effect sizes ranging from .2 to .3). With respect to time to reach maximum erection, 
there were no between-group differences at follow-up; however, abstinent versus 
relapsed participants demonstrated significant across-session improvements (from 
baseline to mid-treatment and from baseline to follow-up). Although successful quitters 
displayed improvements in both maximum tumescence and erectile onset as a result of 
quitting smoking, these across-session changes did not differ significantly from men who 
relapsed. 
 I also hypothesized that abstinent participants’ physiological sexual arousal 
responses at mid-treatment would be intermediate to those assessed at baseline and 
follow-up. Despite these within-group graded improvements, I hypothesized that this 
would not translate to discernable between-group differences at mid-treatment. In line 
with these hypotheses, abstinent participants displayed a graded improvement across time 
for all physiological outcome variables; however, there were no statistical differences at 
mid-treatment between participants who quit smoking and those who relapsed. 
 Taken together, the overall pattern of results were similar to prior studies that 
have shown significant improvements in penile blood flow (Sighinolfi, et al., 2007), as 
well as rigidity and tumescence (Guay, et al., 1998), as a result of smoking cessation. 
Furthermore, results suggested that cessation-induced improvements in genital responses 
were attributable primarily to nicotine elimination (as evidenced by between-group 
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differences in physiological outcome measures at follow-up when successful quitters 
were nicotine/smoke free), rather than tobacco smoke discontinuation alone (i.e., lack of 
statistical between-group differences at mid-treatment). In other words, nicotine alone 
may indeed play a primary inhibitory role with respect to genital hemodynamic 
processes, thereby making men who were wearing the nicotine patch display similar 
results to men who were smoking (relapsed participants). In fact, effect sizes for 
between-group comparisons at follow-up (effect size range: .12 to .33) were 
approximately three times larger than the effect sizes for mid-treatment comparisons 
(effect size range: .01 to .09), suggesting that cessation of isolated nicotine versus 
cessation of tobacco smoke may serve as the chief factor in enhancing physiological 
arousal. These results are in line with prior results demonstrating that isolated nicotine 
hinders male genital responses (Harte & Meston, 2008b).   
6.3 Association between smoking cessation and self-reported sexual arousal 
 Continuous levels of self-reported sexual arousal responses were used as an index 
of psychological sexual arousal during exposure to the erotic stimuli. Because men have a 
relatively salient physiological feedback system (i.e., erection) (Sakheim, et al., 1984), it 
is possible that over time – as a result of smoking-induced impaired erectile responses – 
smokers may synchronize their self-reported sexual arousal to match their inhibited 
genital arousal. Therefore, it was hypothesized that smokers would demonstrate the same 
across-session patterns of both subjective sexual arousal and physiological sexual 
arousal, and therefore subjective sexual arousal responses were expected to increase as a 
result of smoking cessation. 
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 Although all participants demonstrated large and reliable increases in subjective 
sexual arousal during each experimental session, quitting smoking had no differential 
group effect on percent increase in self-reported sexual arousal or on latency to reach 
maximum subjective sexual arousal. There was, however, an association between quitting 
smoking and rate of onset to reach maximum subjective sexual arousal. Specifically, 
abstinent versus relapsed participants demonstrated significant across-session 
improvements (from baseline to follow-up and from mid-treatment to follow-up), 
resulting in between-group differences at follow-up. This suggested that men who were 
successfully smoke-free at follow-up demonstrated faster rates of feeling subjectively 
sexually aroused compared to unsuccessful quitters. In fact, at follow-up, successful 
quitters demonstrated a five-fold enhancement in rate of subjective sexual arousal 
compared to participants who relapsed (effect size = .50 vs .09).   
 To my knowledge, this is the first study that has examined the relationship 
between smoking cessation and subjective sexual arousal responses. Taken together, 
results indicated that, in some circumstances, quitting smoking is associated with 
improved self-reported sexual arousal. This is in line with well-established findings that 
male physiological and self-reported genital responses are correlated with one another 
(Chivers, Seto, Lalumiere, Laan, & Grimbos, 2009), and as such, facets of each domain 
may be improved accordingly by quitting smoking. 
6.4 Association between smoking cessation and self-reported sexual functioning 
A gold-standard self-report measure of sexual functioning was used as an 
ecologically valid way to assess changes in sexual health. As such, this measure 
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complemented the physiological laboratory assessments; it provided a mechanism to 
determine whether statistically significant improvements in physiological sexual arousal 
indices translated to clinically significant changes in sexual function, reflected in the 
participants’ natural environments. It was hypothesized that sexual function would show 
a similar pattern of results compared to sexual arousal measured psychophysiologically. 
Specifically, it was hypothesized that erectile function, orgasmic function, intercourse 
satisfaction, and overall sexual function domains would be significantly higher at follow-
up compared to both the pre-treatment and mid-treatment assessments. I also expected 
the same pattern of results with sexual desire and overall sexual satisfaction, but with 
uncertainty regarding statistical significance.  
Although participants in most cases displayed improvements in sexual function 
domains (erectile function, orgasmic function, sexual desire, intercourse satisfaction, 
overall satisfaction) across time, successful quitters did not show a differential 
improvement compared to participants who relapsed. Similarly, there was no statistically 
significant association between quitting smoking and erectile dysfunction status at either 
mid-treatment or follow-up. However, it deserves mention that successful quitters 
demonstrated a 75% remission rate of ED, and at follow-up only 5% met criteria for ED, 
which is below age-associated norms (Laumann, et al., 1999; Selvin, et al., 2007). In fact, 
relapsed participants were nearly three times as likely to report ED at follow-up 
compared to successful quitters.   
Taken together, results indicated that – unlike results of physiological and 
subjective sexual arousal – men did not show statistically significant improvements in 
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self-reported sexual functioning as a result of smoking cessation. There are a number of 
explanations that could account for this lack of discernable differences. First, it is 
possible that the statistical improvements in physiological arousal responses measured 
within the laboratory setting do not correspond to clinically significant enhancements that 
are discernable to participants in their natural environment. In other words, participant 
may have displayed subtle, albeit statistically significant, changes in erectile capacity that 
were not of sufficient magnitude to noticeably affect their sexual performances in real life 
sexual settings (e.g., penetration, erectile maintenance).  
It is also possible that a 4-week follow-up period is not of sufficient length to 
fully capture improvements in sexual function that are associated with quitting smoking. 
It is feasible that quitting smoking enhances genital responses relatively quickly and in an 
automatic fashion, whereas men’s perceptions of their sexual function (which is, in part, a 
result of partner feedback) may take longer to be reflected as significant augmentations 
via a self-report measure.  
Finally, sexual function domain scores for successful quitters had quite large error 
variances relative to participants who relapsed. This was likely due to the fact that the 
subgroup of successful quitters (n = 20) was relatively small in size compared to 
unsuccessful quitters (n = 45). Although participants generally displayed improvements 
as a function of quitting smoking among sexual function domains, there was not 




6.5   Potential mechanisms of action 
The results of the present study have interesting theoretical implications with 
respect to potential sexual arousal mechanisms that are affected by nicotine/tobacco. That 
participants showed increases in sexual arousal as a function of eliminating 
nicotine/tobacco intake, suggests that nicotine and/or cigarette constituents may 
deleteriously affect underlying components of the sexual arousal process in several ways. 
These individual pathways or interaction of pathways include: (i) central activation, by 
instigating neurotransmitter and/or neuroendocrine effects; (ii) peripheral activation, by 
facilitating SNS activation; or (iii) activation at the biochemical level, by targeting NO 
synthesis directly or indirectly. Complex interactions among these pathways may also 
exist (Sartori, et al., 2005). 
 Nicotine/tobacco affects the central nervous system by causing a cascading dose-
related effect on physiological and biochemical functions (Pomerleau, 1992). After 
cigarette consumption, circulating levels of catecholamines increase, including a 
substantial increase in norepinephrine (Pomerleau & Pomerleau, 1985) (see Figure 27). 
Because norepinephrine is responsible for inhibiting erectile responses (Lincoln & 
Cornell, 1991), it is possible that chronic cigarette consumption reduces sexual arousal 
difficulties in men by attenuating circulating norepinephrine to normal levels, thereby 
facilitating an optimal biochemical environment for adequate genital hemodynamic 




Figure 27: Patterns of Change in Serum Norepinephrine and Epinephrine Levels Relative to Nicotine 
Concentrations Resulting from a Nicotine Exposure.  
Note: approximately 1 mg nicotine content. Mean (+SEM) for 10 smokers who smoked following a 1.5-hour interval 
without cigarettes. Figure from (Pomerleau, 1992).  
 
 
has deleterious effects on modulating the balance between adrenaline and noradrenaline 
(Jeremy & Mikhailidis, 1998).  
The disinhibition of physiological sexual arousal following smoking cessation is 
consistent with literature delineating nicotine’s effects on SNS activity. Specifically, 
nicotine causes cardiovascular constriction (increased heart rate and blood pressure, 
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increased myocardial contractibility) and is primarily responsible for maintaining erectile 
flaccidity (Dean & Lue, 2005). Thus, the enhancement of physiological sexual arousal 
subsequent to the elimination of tobacco smoke and/or nicotine, may be the result of the 
PNS and SNS operating in a relatively more balanced fashion, thereby facilitating 
conditions for optimal erectile responses.  
Quitting smoking may also directly impact biochemical processes underlying 
erection physiology. It has been proposed that free radicals and other compounds within 
cigarettes may decrease the endothelial synthesis of nitric oxide (NO) directly, or 
indirectly by targeting precursors (disrupting the activity of eNOS thereby disrupting the 
conversion of L-arginine to NO), resulting in decreased penile blood inflow (McVary, et 
al., 2001; Zhang, et al., 2006). Considering that NO has been identified as the principal 
neurotransmitter mediating erection (Burnett, et al., 1992; Kim, et al., 1991), it is possible 
that the elimination of both nicotine and tobacco smoke relieves the disruption of 
endothelial synthesis of NO, resulting in enhanced smooth muscle relaxation, 
vasocongestion, and improved erectile response. Another potential pathway that may be 
responsible for inhibiting penile hemodynamic processes is the role of smoking-generated 
carbon monoxide (CO). It has been shown that both exogenous and endogenously formed 
CO can instigate endothelium-dependent vasoconstriction by inhibiting endothelial NO 
formation (Johnson & Johnson, 2003).    
An interesting finding was that there were no differences in physiological sexual 
arousal between participants using a high-dose nicotine patch and participants who were 
smoking cigarettes (i.e., there were no between-group differences at mid-treatment). 
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Furthermore, it was not until participants discontinued the nicotine patch that they 
exhibited significant improvements in sexual health, as compared to when they 
discontinued smoking and wore a nicotine patch. This may suggest that 
pharmacologically active non-nicotine ingredients found within cigarettes have a 
relatively weaker inhibiting effect on sexual arousal compared to nicotine alone. 
However, it should be noted that without measuring the concentration of the drug in vivo 
(via plasma nicotine or plasma cotinine (a by-product of nicotine)) and then covarying for 
these concentrations across conditions, it is impossible to know with certainty which 
nicotine delivery method exerts a more deleterious effect on physiological processes 
underlying sexual arousal.  
 The aforementioned theories on the mechanisms of action of nicotine and tobacco 
smoke on sexual arousal are purely speculative. At present, this complex interaction of 
biochemical, physiological, and psychological mechanisms underlying the sexual 
response process are still not entirely understood. More research at the basic science level 
is needed in order to elucidate the pharmacological role of cigarette smoking on male 
(and female) sexual health.  
6.6   Strengths 
The present study has several strengths. First, to my knowledge, this is the first 
study examining sexual function and smoking cessation that recruited men irrespective of 
ED status. This is especially important, considering that the majority of smokers (under 
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60 years of age‡) would not be expected to have erectile difficulties. Including men both 
with and without ED enables the results to generalize to a significantly larger population 
of men.     
Second, this is the first study to examine changes in sexual health as a result of 
quitting smoking using several physiological indices. Incorporating a variety of genital 
measures provided a way to capture a well-defined and multifaceted overall picture of the 
changes in the penile hemodynamic process.  
Third, the present investigation is the first to examine changes in sexual health via 
a self-report measure. Complementing physiological laboratory assessments with a well-
validated self-report measure of sexual functioning provided a means of assessing 
clinically significant changes. Moreover, including measures of continuous subjective 
sexual arousal responses provided a means to assess the interplay between cognitive 
appraisal of the erotic stimuli and physiologic responses.  
Fourth, this is the first study to examine smoking cessation and sexual health 
using a follow-up period of intermediate length (4 weeks). Previous studies have tested 
men 24 to 36 hours after quitting “cold turkey,” and therefore, it is reasonable to believe 
that both physiological and psychological nicotine withdrawal effects could have affected 
results.   
                                                 
‡ After 60 years of age, the natural age-associated rate of ED increases substantially, with the majority of 
individuals reporting clinically significant erectile difficulties (Laumann, et al., 1999; Martin-Morales, et 
al., 2001; Selvin, et al., 2007). 
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Fifth, this was the first study examining the association between quitting smoking 
and sexual health that has included a comparison control group (relapsed participants), 
thereby enhancing internal validity.  
6.7   Limitations 
 There are a number of limitations of this study that warrant mention. The most 
important limitation is in regard to the study methodology. This was not a clinical trial 
with randomization. The study did, however, use a between-group design, comparing 
relapsed participants (which served as a quasi-control group) to successful quitters; 
however the relapsed group was quite heterogeneous in nature. That is, this group 
comprised individuals who differed in severity of relapse (i.e., full relapse, or partial 
lapse), as well as in timing of relapse (i.e., at the outset of treatment, final week prior to 
the follow-up evaluation). Several statistical steps were taken to ensure adequate 
between-group similarity; however without random group assignments and without a 
bonafide waitlist control condition, one cannot rule out several potential confounding 
factors. For this study the most applicable threats to internal validity would have been 
effects of testing and instrumentation (Kirk, 2009), as well as regression toward the mean 
(Nesselroade, Stigler, & Baltes, 1980).  
 I believe that instrumentation effects (e.g., lack of adequate calibration of 
equipment) would have been minimal, as all equipment was calibrated after each use. I 
believe that regression effects (e.g., a patient seeks help while in an extreme clinical 
 117
state§) would be minimal as well. This was suspected for three reasons: (i) first, one 
would not expect ED to spontaneously remit like other psychological disorders (e.g., 
major depressive disorder); (ii) second, all participants self-referred because they wanted 
to quit smoking, not because they wanted to see improvements in sexual health; and (iii) 
third, only the minority of participants reported erectile difficulties of a clinical nature.  
 The possibility of a potential testing effect (i.e., practice effects, fatigue, 
habituation, sensitization) deserves further mention. It is possible that participants may 
have become either more sensitive to the erotic stimuli and/or more relaxed during each 
subsequent session (e.g., less anxiety, less distracting performance-evaluative thoughts), 
which could have resulted in higher sexual arousal at follow-up, thus masking the effects 
of the treatment intervention. I could find no literature documenting the effect of across-
trial sensitization in male genital responding to erotic cues. Rather, literature points to 
habituation effects in some circumstances. Specifically, it has been shown that men 
display significantly reduced physiological and subjective sexual arousal responses to the 
same erotic stimulus both within- and across- trials (O'Donohue & Plaud, 1991; Plaud, 
Gaither, Henderson, & Devitt, 1997). However, men do not show differences in either 
physiological or subjective sexual arousal either within- or across- experimental sessions 
when the stimuli are varied (O'Donohue & Plaud, 1991; Plaud, et al., 1997). Because the 
current study incorporated varied erotic stimuli to which participants were 
counterbalanced, one should not expect any association between testing effects and 
sexual arousal (either habituation or sensitization). Furthermore, it should be noted that 
                                                 
§ In this case, an extreme state of ED. 
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changes in affect did not covary with any of the primary outcome variables, indicating 
that increases in sexual health were in fact due to the removal of nicotine and tobacco-
smoke which were likely responsible for causing deleterious effects on erectile 
hemodynamic responses. Finally, because between-group statistical differences were  
found with respect to both physiological and sexual arousal outcome measures, this 
suggests that testing effects were minimal at best.      
 A second limitation is that smoking abstinence was determined by self-report 
rather than by biochemical verification (e.g., expired air carbon monoxide, thiocyanate 
(SCN), serum nicotine, serum cotinine). As such, it is impossible to determine whether 
participants accurately reported their cigarette use. It should be noted that all participants 
provided saliva samples at each visit and were spuriously informed that these samples 
would be assayed for cotinine content (a byproduct of nicotine that has a relatively long 
half-life), and verified with their self-report (i.e., the bogus pipeline technique (Jones & 
Sigall, 1971)). This technique has been shown to produce reliable and accurate estimates 
of smoking (Murray, O'Connell, Schmid, & Perry, 1987). In studies in which participants 
have actually been asked to provide biochemical samples prior to reporting their smoking 
levels, little underreporting has generally been found (Bauman & Dent, 1982; Luepker, et 
al., 1981; Pechacek, et al., 1984). Additionally, in a meta-analysis that examined the 
concordance between self-reported smoking and biological verification of smoking 
activity (N = 36,830), it was determined that self reports of smoking were quite accurate 
(Patrick, et al., 1994). 
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 A third limitation is with respect to the dropout rate; only 53% of participants 
completed the follow-up session. In order to address this issue, several steps were taken 
to ensure the reliability of the observed effects. As such, data were analyzed using list-
wise deletion, last observation carried forward (LOCF), and with missing data estimation 
(full information maximum likelihood (FIML)). In fact, FIML is considered a ‘‘state-of-
the-art’’ approach (J.L. Schafer & Graham, 2002) and has been shown to produce more 
accurate parameter estimates than either list-wise deletion or LOCF (Enders, 2001; 
Enders & Bandalos, 2001; J.L. Schafer & Graham, 2002). Additionally, Little and Rubin 
(2002) and Schafer (1997) have both suggested that data estimation methods using FIML 
can reliably be used when up to 90% of the data are missing for a particular variable.
 The formulation of outcome groups (abstinent vs. relapsed) also deserves 
mention. Because completely abstinent men (zero cigarettes during a 7-day point 
prevalence) and partially abstinent men (0 to 3 cigarettes/day during 7-day point 
prevalence) did not show any differences with respect to their changes in sexual health as 
a function of smoking cessation, these two groups were combined for the initial analyses 
among the subgroup of successful smokers. As such, this entire group was considered 
“nonsmokers.” Although results show that significantly reducing tobacco consumption 
(but not completely eliminating smoking) significantly enhances sexual health, this 
should in no way be interpreted to mean that smoking 1 to 3 cigarettes per day poses no 
health hazards. Although the risk of cancer decreases in a dose-dependent fashion with 
reduction in smoke exposure, individuals smoking a few cigarettes per day still have a 
nearly 5-fold risk of cancer (U.S. Department of Health and Human Services, 1989). 
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Furthermore, smoking even a few cigarettes per day increases the risk of heart disease 
mortality (Bjartveit & Tverdal, 2005) and respiratory diseases (Bohadana, Nilsson, 
Westin, Martinet, & Martinet, 2006) nearly as much as smoking a pack per day. With 
these data in mind, all individuals should aim to be completely abstinent.  
 Another limitation is with respect to the sample size. Although this study used a 
repeated-measures design, which enhances statistical power, the sample sizes of the 
outcome groups for the intent-to-treat analyses were still relatively low, especially for the 
subgroup of successful quitters (n = 20). Thus, there was not sufficient power to detect 
several group×time interactions, particularly for sexual function measures (post-hoc 
power range: .14 to .36).  
 The generalizability of the sample is also another potential limitation of this 
study. Considering that this study was sexual in nature, biases among participants 
participating in sexuality research should also be considered. Specifically, compared to 
non-volunteers, those who self-select for sexuality research tend to be more sexually 
experienced, have less traditional sexual attitudes, endorse greater sexual sensation 
seeking, and are more interested in sexually explicit materials (Brecher & Brecher, 1986; 
D. Saunders, Fisher, Hewitt, & Clayton, 1985; Wiederman, 1999; Wolchik, Braver, & 
Jensen, 1985).  
 In this study, erectile dysfunction was assessed via a self-report measure, and 
therefore participants did not undergo a clinical evaluation in order to be diagnosed 
according to medical guidelines (i.e., DSM-IV-TR or ICD-10 (World Health 
Organization, 1993)). Considering that classification of ED in this study was to serve as a 
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primary endpoint, rather than understanding the etiology and type of erectile difficulty, 
using the IIEF seemed quite appropriate. Furthermore, the IIEF has been adopted as the 
“gold standard” measure for brief evaluation of self-reported erectile functioning and has 
been used in more than 50 clinical trials (RC Rosen, Cappelleri, & Gendrano, 2002).   
6.8   Clinical implications 
 The results of this study have important clinical implications. Results have the 
possibility to serve as an important mechanism to enhance men’s interest and 
commitment to quit smoking, considering that they may show an increase in erection, as 
well as increases in subjective sexual arousal. Simply stated, if men do not want to quit 
smoking for their heart or for their lungs, perhaps they would consider quitting for 
increased sexual performance. In addition to discussing traditional acute (e.g., enhanced 
cardiovascular and pulmonary functioning) and long-term (e.g., reduced morbidity and 
mortality from cancer, lung disease, and heart disease) benefits of quitting smoking with 
patients, healthcare providers may find it useful to discuss the acute benefits of quitting 
smoking in terms of increased erectile performance.  
 These results may also have implications for therapeutic patient screening. It has 
been shown that providing patients with feedback on adverse changes associated with 
smoking can increase the salience of the negative impact of smoking to patients’ health 
and consequently improve quit rates (Bovet, Perret, Cornuz, Quilindo, & Paccaud, 2002). 
As such, patients may benefit from receiving feedback of their actual erectile responses 
while smoking, and again pre- and post NRT. This “scientific evidence” that they are 
showing improvements in sexual health may serve as an important motivation to continue 
 122
with the cessation process, as well as maintain their newly acquired smoke-free lifestyle. 
This would likely increase self-efficacy, confidence, and autonomy, all of which are 
associated with successful cessation (Williams, Gagné, Ryan, & Deci, 2002). 
 These results are widely generalizable in that these data hold for heavy smoking 
men aged 23-60, irrespective of self-reported erectile difficulties. That is, even men who 
do not complain of erectile problems may still benefit sexually from quitting smoking. In 
fact, evidence suggests that smoking may have a stronger deleterious effect on sexual 
functioning in young male smokers compared to older male smokers (Gades, et al., 
2005). Therefore, these results may serve as an important motivator – particularly for 
young men who may put considerable importance on their erectile performance – to 
consider quitting smoking. 
A final point to mention is that the laboratory-assessed changes in genital arousal 
did not corresponded to noticeable enhancements in sexual function. That is, the data do 
not necessarily suggest that quitting smoking is a feasible way to treat ED (at least in the 
short-term). Rather, it is hoped that these statistical findings of cessation-induced sexual 
health enhancements may ultimately promote men to quit smoking. Therefore, the data 
may serve as a novel means to alleviate smoking-associated morbidity and mortality.   
6.9   Public health implications 
Although the rate of cigarette smoking is declining in the Unites States, it is still 
not nearly sufficient to meet the National Health Service’s objective to reduce the 
prevalence of cigarette smoking among adults to <12% (Centers for Disease Control and 
Prevention, 2006). The public health burden due to smoking is enormous. There are 
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approximately 1 billion current smokers worldwide, causing an estimated 200 billion in 
economic damages each year based on the costs to treat tobacco-related illnesses and the 
indirect costs associated with disability (Zaher, Halbert, Dubois, George, & Nonikov, 
2004). The worldwide death toll from smoking is expected to rise from 5 million to 10 
million people per year by the year 2030 (Ezzati & Lopez, 2003), and the World Health 
Organization anticipates that tobacco will become the largest single health problem by 
the year 2020 (Vainio, Weiderpass, & Kleihues, 2001). With these alarming statistics in 
mind, help from all sources is needed in order to ameliorate the negative impact of 
cigarette smoking on health.  
It is hoped that the results of the present study may serve as a novel means to 
facilitate programs and interventions targeting the prevention and cessation of cigarette 
smoking in men. In particular, these results have the potential to influence practitioners to 
discuss with male patients the benefits of starting the quitting process. Enhancing 
successful smoking cessation in men would significantly enhance quality of life, 
substantially reduce premature death, and alleviate enormous economic burdens caused 
by smoking-related diseases such as cardiovascular disease, respiratory disease, and 
cancer. Moreover, facilitating patients to quit smoking not only enhances their own 
quantity and quality of life, but also improves the long-term health of patients’ families 
and friends. In fact, approximately 40,000 nonsmokers in the United States die 
prematurely each year due to secondhand smoke exposure (Centers for Disease Control 
and Prevention, 2005).   
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6.10   Conclusions 
The results of the present investigation provide the first empirical evidence that 
smoking cessation significantly enhances both physiological and self-reported indices of 
sexual health in long-term male smokers, irrespective of baseline erectile impairment. 
These results have the potential for facilitating programs and interventions targeting the 




International Index of Erectile Function  
Rosen, Riley, Wagner, Osterloh, Kirkpatrick, & Mishra (1997) 
 
 
INSTRUCTIONS: These questions ask about your sexual feelings and responses during the 
past 4 weeks. Please answer the following questions as honestly and clearly as possible. 
Your responses will be kept completely confidential. Check only one box per question 
 
 
1. Over the past 4 weeks, how often were you able to get an erection during sexual activity? 
 1 = Almost never/never 
 2 = A few times (much less than half the time) 
 3 = Sometimes (about half the time) 
 4 = Most times (much more than half the time) 
 5 = Almost always/always 
 0 = No sexual activity 
 
2. Over the past 4 weeks, when you had erections with sexual stimulation, how often were your 
erections hard enough for penetration? 
  1 = Almost never/never 
  2 = A few times (much less than half the time) 
  3 = Sometimes (about half the time) 
  4 = Most times (much more than half the time) 
  5 = Almost always/always 
  0 = Did not attempt intercourse 
 
3. Over the past 4 weeks, when you attempted sexual intercourse, how often were you able to penetrate 
(enter) your partner? 
 1 = Almost never/never 
 2 = A few times (much less than half the time) 
 3 = Sometimes (about half the time) 
 4 = Most times (much more than half the time) 
 5 = Almost always/always 
  0 = Did not attempt intercourse 
 
4. Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your erection 
after you had penetrated (entered) your partner? 
  1 = Almost never/never 
  2 = A few times (much less than half the time) 
  3 = Sometimes (about half the time) 
  4 = Most times (much more than half the time) 
  5 = Almost always/always 
  0 = Did not attempt intercourse 
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5. Over the past 4 weeks, during sexual intercourse, how difficult was it to maintain your erection to 
completion of intercourse? 
1 = Extremely difficult 
2 = Very difficult 
3 = Difficult 
4 = Slightly difficult 
5 = Not difficult 
0 = Did not attempt intercourse 
 
6. Over the past 4 weeks, how many times have you attempted sexual intercourse? 
 1 = One to two attempts 
 2 = Three to four attempts 
 3 = Five to six attempts 
 4 = Seven to ten attempts 
 5 = Eleven + attempts 
 0 = No attempts 
 
7. Over the past 4 weeks, when you attempted sexual intercourse, how often was it satisfactory? 
 1 = Almost never/never 
 2 = A few times (much less than half the time) 
 3 = Sometimes (about half the time) 
 4 = Most times (much more than half the time) 
 5 = Almost always/always 
 0 = Did not attempt intercourse 
 
8. Over the past 4 weeks, how much have you enjoyed sexual intercourse? 
 1 = No enjoyment 
 2 = Not very enjoyable 
 3 = Fairly enjoyable 
 4 = Highly enjoyable 
 5 = Very highly enjoyable 
  0 = No intercourse 
 
9. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you 
ejaculate? 
 1 = Almost never/never 
 2 = A few times (much less than half the time) 
 3 = Sometimes (about half the time) 
 4 = Most times (much more than half the time) 
 5 = Almost always/always 
 0 = No sexual stimulation/intercourse 
 
10. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you have the 
feeling of orgasm or climax? 
 1 = Almost never/never 
 2 = A few times (much less than half the time) 
 3 = Sometimes (about half the time) 
 4 = Most times (much more than half the time) 
 5 = Almost always/always 
 0 = No sexual stimulation/intercourse 
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11. Over the past 4 weeks, how often have you felt sexual desire? 
 1 = Almost never/never 
  2 = A few times (much less than half the time) 
  3 = Sometimes (about half the time) 
  4 = Most times (much more than half the time) 
  5 = Almost always/always 
 
12. Over the past 4 weeks, how would you rate your level of sexual desire? 
 1 = Very low/none at all 
 2 = Low 
 3 = Moderate 
 4 = High 
 5 = Very high 
 
13. Over the past 4 weeks, how satisfied have you been with your overall sex life? 
 1 = Very dissatisfied 
 2 = Moderately dissatisfied 
 3 = About equally satisfied and dissatisfied 
 4 = Moderately satisfied 
 5 = Very satisfied 
 
14. Over the past 4 weeks, how satisfied have you been with your sexual relationship with your partner? 
 1 = Very dissatisfied 
 2 = Moderately dissatisfied 
 3 = About equally satisfied and dissatisfied 
 4 = Moderately satisfied 
 5 = Very satisfied 
 
15. Over the past 4 weeks, how do you rate your confidence that you could get and keep an erection? 
 1 = Very low 
 2 = Low 
 3 = Moderate 
 4 = High 







 Domain Items                 Score Range  Min score Max score 
 EF  1,2,3,4,5,15 0 (or 1) – 5  1  30  
 OF  9,10  0-5   0  10 
 SD  11,12  1-5   2  10 
 IS  6,7,8  0-5   0  15 
 OS  13,14  1-5   2  10 
 





Kinsey Sexual Orientation Scale 
Kinsey, Pomeroy, & Martin (1948) 
 
 




0.  Exclusively heterosexual with no homosexual 
1.  Predominantly heterosexual, only incidentally homosexual 
2.  Predominantly heterosexual, but more than incidentally homosexual 
3.  Equally heterosexual and homosexual 
4.  Predominantly homosexual, but more than incidentally heterosexual 
5.  Predominantly homosexual, only incidentally heterosexual 







Alcohol Use Disorders Identification Test 





Drug Abuse Screening Test  




Fagerstrom Test for Nicotine Dependence  
Heatherton, Kozlowski, Frecker, & Fagerstrom (1997) 
 
 
1.  How soon after you wake up do you smoke your first cigarette? 
  After 60 minutes (0) 
  31-60 minutes (1) 
  6-30 minutes (2) 
  Within 5 minutes (3) 
 
2.   Do you find it difficult to refrain from smoking in places where it is forbidden? 
  No (0) 
   Yes (1)  
 
3.   Which cigarette would you hate most to give up? 
  The first in the morning (1) 
  Any other (0) 
 
4.   How many cigarettes per day do you smoke? 
   10 or less (0) 
   11-20 (1) 
   21-30 (2) 
   31 or more (3) 
 
5.   Do you smoke more frequently during the first hours after awakening than during the 
rest of the day? 
   No (0) 
   Yes (1) 
 
6.   Do you smoke even if you are so ill that you are in bed most of the day? 
   No (0) 







0-2    Very low dependence 
3-4    Low dependence  
5       Medium dependence 
6-7    High dependence 




Positive and Negative Affect Schedule  
Watson, Clark, & Tellegen (1988) 
 
This scale consists of a number of words that describe different feelings and emotions.  
Read each item and then circle the appropriate number that indicates to what extent you 
feel this way right now. 
 
 
  very 
slightly or 






quite a bit 
 
extremely 
1. interested 1 2 3 4 5 
2. distressed 1 2 3 4 5 
3. excited 1 2 3 4 5 
4. upset 1 2 3 4 5 
5. strong 1 2 3 4 5 
6. guilty 1 2 3 4 5 
7. scared 1 2 3 4 5 
8. hostile 1 2 3 4 5 
9. enthusiastic 1 2 3 4 5 
10. proud 1 2 3 4 5 
11. irritable 1 2 3 4 5 
12. alert 1 2 3 4 5 
13. ashamed 1 2 3 4 5 
14. inspired 1 2 3 4 5 
15. nervous 1 2 3 4 5 
16. determined 1 2 3 4 5 
17. attentive 1 2 3 4 5 
18. jittery 1 2 3 4 5 
19. active 1 2 3 4 5 




Systematic Assessment for Treatment Emergent Events  









Study ID#: SCS32 Dosage  regimen: 21m g (3 weeks);
Age: 43      14mg (3 weeks), 7m g (1 week)
Visit 1 Visit 2 V isit 3 Change f rom Baseline: 
Weight (lbs) 161.40 158.40 159.60 -1.80
Height (in .) 77.00 77.00 77.00 0.00
BMI  (kg /m2) 18.78 18.43 18.57 -0.21
Visit 1 Visit 2 V isit 3 Change f rom Baseline: 
Systolic B lood  Pressure (mm  Hg) 116 129 121 5
Diastolic B lood  Pressure (mm  Hg) 82 80 63 -19
Heart Ra te (BPM) 87 76 91 4
   *Based on the 15 item self-report questionnaire
Visit 1 Visit 2 V isit 3 Change f rom Baseline: 
Arousal 29 27 29 0
Orgasm 7 8 10 3
Desire 10 8 8 -2
Sexual Sa tisfaction 12 10 13 1
Overall Satisfaction 10 9 10 0
      †Recorded continuously with  an optical mouse
Vis it 1 Visit 2 Visit 3 Change f rom Baseline: 
Percent Increase ¶ 53.9731211 22 .52607 86 .04038 32.07
Page 1 of 2
Patch treatment length: 7 weeks
Date of V isit 3: 9/24/2009
QUIT SMOKING STUDY - Health Feedback Report
Date of V isit 1: 7/1/2009Name: John Cuddeback
Date of V isit 2: 7/23/2009
¶ Calcu la ted as the percent increase from the mean arousal during the 
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Neutral Erotic Neutral Erotic Neutral Erotic
11.2770724 11.46964 11.96363 12.2859 11.83583 12.61859
Sexual Arousal (Physiological) - Time to maximum erection  
Visit 1 Visit 2 Visit 3 Change from Baseline:
Time (seconds) 420.00 189.00 126
Page 2 of 2
Mean Circumference (cm)¶
Visit 1 Visit 2 Visit 3
-294.00
¶ Calculated as the mean circumference during the neutral film segment and the mean circumference 





























































BMI – Body mass Index is a statistical measurement which compares a person's weight 
and height. Though it does not actually measure the percentage of body fat, it is a useful 
tool to estimate a healthy body weight based on how tall a person is.  
 
Over the course of the study, you have lost 1.8lbs. Based on your current BMI of 18.57 
you are currently within the normal weight range.  
 
Blood Pressure - For each heartbeat, blood pressure varies between systolic and 
diastolic pressures. Systolic pressure is peak pressure in the arteries. Diastolic pressure 
is minimum pressure in the arteries, which occurs near the beginning of the cardiac 
cycle when the ventricles are filled with blood. 
 
Over the course of the study, your systolic Blood pressure increased by 5 units and your 
diastolic blood pressure decreased by 19 units. Your current blood pressure of 121/63 is 
currently within the normal range.  
 
Heart Rate - is a measure of the number of heart beats per minute (bpm). The average 
resting human heart rate is about 70 bpm for adult males and 75 bpm for adult females. 
 
Over the course of the study, your heart rate increased by 4 bpm. Your current heart rate 
of 91 bmp is currently within the normal range.  
 
Sexual Functioning - Level of sexual functioning was assessed at each session with 
the International Index of Erectile Function (IIEF). The IIEF is the most widely used index 
of erectile function and is a 15-item measure assessing five-factor areas of male sexual 
functioning: erectile function, orgasmic function, sexual desire, intercourse satisfaction, 
and overall satisfaction.  
 
Over the course of the study, your erectile function score remained unchanged; your 
orgasmic function score remained increased by 3 points; your sexual desire score 
decreased by 2 points; your sexual satisfaction score increased by 1 point; and your 
overall satisfaction score remained unchanged. Overall, your self-reported sexual 
functioning slightly improved from baseline to follow-up. 
 
Self-Reported Sexual Arousal - Continuous subjective sexual arousal was measured 
using a hand-controlled device which consisted of a computer optical mouse mounted 
on a wooden track divided into seven equally spaced intervals, where 0 indicated 
neutral, and 1–7 reflected increasingly higher levels of feeling sexually aroused. Sexual 
arousal was calculated within each session as the percent increase from the mean 
arousal during the neutral film segment to the mean arousal during the erotic film 
segment.  
 
Over the course of the study, your self-reported sexual arousal increased by 32 
percentage units.  
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Physiological Sexual Arousal – genital sexual arousal was assessed via penile 
circumferential change using a mercury-in-rubber strain gauge positioned mid-shaft on 
the penis. Physiological sexual arousal was calculated as the circumferential change in 
cm from the mean arousal during the neutral film segment to the mean arousal during 
the erotic film segment. Physiological sexual arousal was also measured by calculating 
the amount of time to reach your maximum erection during each visit.  
 
Over the course of the study, your physiological sexual response significantly increased.  
 
Additionally, the amount of time to reach your maximal erection decreased by 294 
seconds. This indicates that you are now able to reach your maximum erection in less 
time compared to when you were smoking (during visit 1). 
 
Overall Summary of Results: Throughout the course of the study, you showed an 
increase in cardiovascular health as demonstrated by your lowered blood pressure. 
Furthermore, your physical health improved as you lost 1.8lbs and your BMI score 
decreased. You had a slight increase in self-reported sexual functioning. Finally, you 
showed a significant increase in self-reported sexual arousal and physiological sexual 
arousal.   
 
We appreciate your participation in this study! Feel free to contact us at the 
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